

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE FORM PTO-1390 (REV. 11-2000)		ATTORNEY'S DOCKET NUMBER 0933-0170P
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 09/936823
INTERNATIONAL APPLICATION NO. PCT/FI00/00249	INTERNATIONAL FILING DATE March 24, 2000	PRIORITY DATE CLAIMED March 25, 1999
TITLE OF INVENTION PROCESS FOR PARTITIONING OF PROTEINS		
APPLICANT(S) FOR DO/EO/US PENTTILÄ, Merja; NAKARI-SETÄLÄ, Tiina; FAGERSTRÖM, Richard; SELBER, Klaus; KULA, Maria-Regina; LINDER Markus; and TJERNELD Folke		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39 (1).</p> <p>4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).</p> <p><input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <p>a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). WO 00/58342</p> <p>b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau.</p> <p>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p><input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).</p> <p>a. <input type="checkbox"/> is transmitted herewith.</p> <p>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4)</p> <p><input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</p> <p>b. <input type="checkbox"/> have been transmitted by the International Bureau.</p> <p>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p>d. <input checked="" type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>		
Items 11. to 20. below concern document(s) or information included:		
<p>11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98, Form PTO-1449(s), and International Search Report (PCT/ISA/210) with 13 cited document(s) and Finnish Search Report.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A FIRST preliminary amendment.</p> <p>14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>17. <input checked="" type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825.</p> <p>18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p> <p>20. <input checked="" type="checkbox"/> Other items or information:</p> <p>1. International Preliminary Examination Report (PCT/IPEA/409)</p> <p>2. Twenty-eight (28) pages of formal drawings</p> <p>3. Nineteen (19) pages containing Sequence Listing</p>		

U.S. APPLICATION NO (if known, see 37 CFR 1.5)	INTERNATIONAL APPLICATION NO	ATTORNEY'S DOCKET NUMBER		
09/936823	PCT/FI 00/00249	0933-0170P		
21. <input checked="" type="checkbox"/> The following fees are submitted:		CALCULATIONS PTO USE ONLY		
BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5):				
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO.		\$1,000.00		
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO		\$860.00		
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO.		\$710.00		
International preliminary examination fee (37 CFR 1.482) paid to USPTO if all claims did not satisfy provisions of PCT Article 33(1)-(4)		\$690.00		
International preliminary examination fee (37 CFR 1.482) paid to USPTO if all claims satisfied provisions of PCT Article 33(1)-(4)		\$100.00		
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$ 1,000.00		
charge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		\$ 130.00		
CLAIMS		NUMBER FILED	NUMBER EXTRA	RATE
al Claims	51 - 20 =	31	X \$18.00	\$ 558.00
dependent Claims	1 - 3 =	0	X \$80.00	\$ 0.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)		Yes	+ \$270.00	\$ 270.00
TOTAL OF ABOVE CALCULATIONS =		\$ 1,958.00		
Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.		\$		
SUBTOTAL =		\$ 1,958.00		
lessing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).		\$ 0.00		
TOTAL NATIONAL FEE =		\$ 1,958.00		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property		\$ 0.00		
TOTAL FEES ENCLOSED =		\$ 1,958.00		
		Amount to be: refunded	\$	
		charged	\$	
<p>a. <input checked="" type="checkbox"/> A check in the amount of <u>\$ 1,958.00</u> to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>02-2448</u>.</p>				
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.				
Send all correspondence to: Birch, Stewart, Kolasch & Birch, LLP or Customer No. 2292 P.O. Box 747 Falls Church, VA 22040-0747 (703)205-8000				
Date: <u>September 18, 2001</u>		By <u>G. M. Murphy #36613</u> Gerald M. Murphy, Jr., #28,977		

PATENT
0933-0170P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: PENTTILÄ, Merja et al. Conf.: Unknown
Appl. No.: NEW Group: Unknown
Filed: September 18, 2001 Examiner: Unassigned
For: PROCESS FOR PARTITIONING OF PROTEINS

AMENDMENT**BOX PATENT APPLICATION**

Assistant Commissioner for Patents
Washington, DC 20231

September 18, 2001

Sir:

The following preliminary Amendments and Remarks are respectfully submitted in connection with the above-identified application.

AMENDMENTS

Please amend the specification as follows:

Before line 1, insert

--This application is the national phase under 35 U.S.C. §371 of PCT International Application No. PCT/FI00/00249 which has an International filing date of March 24, 2000, which designated the United States of America and was published in English.--

REMARKS

The specification has been amended to provide a cross-reference to the previously filed International Application.

A Sequence Listing is part of the present application; the Sequence Listing is provided in Computer Readable Form on an attached diskette. Applicant submits that the content of the CRF file 36838SEQ.TXT is identical to the printed copy of the Sequence Listing attached hereto. No new matter is added by the Sequence Listing.

Should there be any outstanding matters that need to be resolved in the present application, the Examiner is respectfully requested to contact the undersigned below, to conduct an interview in an effort to expedite prosecution in connection with the present application.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees

Appl. No. New

required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By Gerald M. Murphy, Jr. #36,623
Gerald M. Murphy, Jr., #28,977

GMM/jeb
1163-0355P

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

Attachment: Version with Markings to Show Changes Made

(Rev. 02/12/01)

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

The specification was amended to provide cross-referencing to the International Application.

28/10/01

WO 00/58342

PCT/FI00/00249

PROCESS FOR PARTITIONING OF PROTEINS**Field of the invention**

5 The present invention relates to isolation and purification of proteins in aqueous two-phase systems (ATPS). Specifically the invention provides processes for partitioning of molecules of interest in ATPS by fusing said molecules to targeting proteins which have the ability of carrying said molecule into one of the phases.

10 Background of the invention

Liquid-liquid extraction in an aqueous two-phase system (ATPS) can offer a powerful technique for isolation and purification of proteins. The separation of macromolecules and particles by means of liquid-liquid extraction is well known (Albertsson, 1986; Walter *et al.*, 1985; Kula, 1990). Mainly polyethylene glycol (PEG) - salt, PEG-dextran and PEG-starch systems have been in use. More recently detergents and detergents with reversed solubility were discovered as suitable methods for separation of macromolecules, and especially for the separation of proteins.

15 An advantage of aqueous two-phase systems (ATPS) is that they are especially suited for large scale processing of microbial proteins not only from culture supernatants but also from crude extracts containing cells and cell debris (Kula, 1979; Kula, 1985). Characteristic features of biological fluids as well as suspensions are rather small particle sizes, low density differences between fluid and suspended solids, high viscosities of the extracts and high 20 compressibility of the solids (Hustedt *et al.*, 1985; Bender and Koglin, 1986). These attributes decrease the performance of conventional methods for solid-liquid separation like centrifugation and filtration at the beginning of a protein recovery process. Using an aqueous two-phase system removal of solids can be integrated into a liquid-liquid separation 25 step, clarification is thus combined with an initial purification (Kula, 1979; Kula, 1985)

30 After the extraction process phase separation can be accomplished by settling under gravity as well as by centrifugation (Kula, 1985). ATPS can be applied in various scales from very

small laboratory scale to large industrial scale thus suiting for various proteins, purposes and needs. With regard to industrial purposes commercially available centrifugal separators can be used to shorten separation time. Several authors have investigated the potential of centrifugal separators of various design for processing of large volumes of aqueous two phase systems (Kula, 1979; Kula *et al.*, 1981, Kula *et al.*, 1982; Kula, 1985). In these studies the authors have used polymer/polymer or polymer/salt systems and the results of these investigations demonstrate the feasibility of continuous separation of aqueous two-phase systems in centrifugal separators.

10 Extraction systems based on nonionic surfactants have been described as an alternative to standard polymer/polymer or polymer/salt systems. Phase forming surfactants are e.g. polyoxyethylene type nonionic detergents. The basis of this type of aqueous two-phase system is the temperature-dependent reversible hydration of the polar ethylene oxide head groups. The temperature at which the phase separation occurs is referred to as the cloud-point (cloud-point extraction). This kind of aqueous two-phase system is especially suited for the extraction of amphiphilic biomolecules. The potential of this type of two-phase system for separating membrane bound proteins from cytosolic and peripheral membrane proteins was first demonstrated by Bordier (1981). Heusch and Kopp (1988) have been able to demonstrate that lamellar structures formed in the miscibility gaps of polyglycol ether /

15 water systems are responsible for the selective extraction of hydrophobic substances.

20

Recently, the successful application of a surfactant-based aqueous two-phase system for the extraction of a membrane bound protein (cholesterol oxidase) from the unclarified culture medium of the gram-positive microorganism *Nocardia rhodochrous* on a bench scale has

25 been reported (Minuth *et al.*, 1995). By addition of only one chemical compound a product release through solubilization was possible in homogeneous phase and in a second step a clarification as well as an initial purification was achieved by an extraction process at elevated temperatures separating the detergent rich phase. A closed concept was further developed for the production of the membrane bound enzyme by surfactant-based

30 extraction, organic solvent extraction and anion-exchange chromatography, which gave a product suitable for analytical applications (Minuth *et al.*, 1996).

In aqueous two phase systems the desired target e.g. a protein should partition selectively into one phase (preferentially the lighter phase) while the other substances should partition into the other phase (preferentially the heavier phase). In PEG/salt and PEG/dextran and similar systems there are several driving forces for a substance like charges, hydrophobic, 5 hydrophilic forces or the dependence on conformation or ligand interaction (Albertsson, 1986). The forces leading to separation in detergent based aqueous two phase systems are suggested to be primarily hydrophobic (Terstappen *et al.*, 1993). Even if a lot of work has been carried out in the field of prediction in ATPS, none of the designed models provides a physical picture of the phase behaviour and prediction is hardly possible (Johansson *et al.*, 10 1998).

In ATPS the partitioning coefficient is defined as the concentration (activity in case of an enzyme) of the target in the top phase divided by the concentration (enzyme:activity) of the target protein in the bottom phase. Partitioning coefficients in ATPS systems are usually in 15 the range from less than 1 up to less than 100 (Terstappen *et al.*, 1992; Terstappen *et al.*, 1993).

$$K = \frac{c_{i,T}}{c_{i,B}}$$

Yield: is defined as the amount of target in the top phase divided by the sum of the amount of target in top and bottom. This leads to the following equation

$$20 \quad Y_T = \frac{1}{1 + \left[\frac{V_B}{V_T} \cdot \frac{1}{K} \right]}$$

If the desired substance is directed to the heavier phase (as it can be the case using Triton) the yield is defined by

$$Y_B = \frac{1}{1 + \left[\frac{V_T}{V_B} \cdot K \right]}$$

The volume ratio of the two coexisting phases are defined by the volumes of the lighter over the heavier phase, respectively.

$$R = \frac{V_T}{V_B}$$

5 An example of useful proteins facing problems in purification in a cost-effective way are the commonly used industrial enzymes used as biocatalysts, the glycosyl hydrolases, proteases and lipases produced by fungi and bacteria. These are used in e.g. laundry, textile, paper and pulp, food and feed industry. The fact that microbes produce many different enzymes during their growth and the fact that some of these may be undesired in certain applications leads
10 to a need to enrich the active component(s). This enrichment can be performed by choosing appropriate growth conditions, by genetic engineering and/or by down-stream processing (e.g. purification of the active component(s)).

15 Purification of proteins are generally performed by chromatography. Usually gel-chromatographic methods are used based on ion-exchange, hydrophobic interaction, affinity chromatography and molecular sieving. Methods like electrophoresis and crystallisation can also be used. These methods are well known in the art and suitable for proteins of fairly high market value. In case of bulky enzyme production these methods, however, are too expensive in order to keep the final product on a compatible price level. Due to similar
20 properties of these enzymes several purification steps are usually needed to separate the proteins from each other. This often causes low final yields and therefore a high loss of product.

25 Many extracellular hydrolases produced by the filamentous fungus *Trichoderma* are currently used in different industrial applications in large scale. These hydrolases are e.g. hemicellulases (such as xylanases and mannanases), cellulases (such as endoglucanases and cellobiohydrolases) and proteases. Purification of these is well known in the art (Bhikhabhai *et al.*, 1984; Pere *et al.*, 1995), but for large industrial applications the purification methods are too expensive. Alternative methods to enrich these hydrolases have been used, including
30 deletion of undesired genes by genetic engineering (Suominen *et al.*, 1992). However, even

after extensive genetic engineering some minor undesired activities may still be present in the final product.

ATPS have been studied in purification of cellulases of *T. reesei* and the purification of an 5 endoglucanase III showed some promising results, enriching the yield of the protein in the upper phase (U.S. Pat. 5,139,943). ATPS have also been studied in purification of lipases, endoxylanase and natamycin (EP 0 574 050 A1). No K and Y values are, however, mentioned.

10 As in other protein purification methods, similar properties of proteins produced by an organism impair also in ATPS, e.g. selective separation of one protein is not achieved optimally. To obtain selectivity in purification affinity chromatographic methods are used especially for analytic purposes and in purification of high-value products. These include immunoaffinity chromatography and various fusion protein strategies well described in the 15 art such as fusing the protein of interest to an other protein (e.g. glutathione-S-transferase), protein domain (e.g. protein A-ZZ domain) or small peptide (e.g. His-tag), which selectively bind to the solid carrier and thus the recovery of the fusion partner is obtained as well. The fusion protein can be suitable for the particular purpose as such or cleavage of the product from the added fusion partner may be desired. There are well-known methods in the art on 20 cleavage of fusion proteins from their partners by proteases, e.g. by factor X, thrombin or papain or by genetically introducing a protease cleavage site (e.g. Kex2 site) or autoproses- sing domains (e.g. Intein, New England Biolabs) or by chemical cleavage (e.g. CNBr).

ATPS offer advantages mainly with respect to technology compared with the solid state 25 based separation systems e.g. affinity column-based techniques. The scale-up of extractive enzymes is relatively simple utilising commercially available equipment and machinery common in the chemical industry. In addition, it can be used in a continuous process and it can be relatively cost extensive. It can be used as a single step for clarification, concentration and purification. ATPS can be used as a first capture-step, but for bulk products often no 30 further purification is needed.

To aid selective separation in two-phase systems, recent publications have described the fusion of small peptide tags of 12 amino acids to the protein to be purified. The most successful of these soluble peptides are containing tryptophans. So far they have mainly been applied for very small molecules like the staphylococcal protein A derivative ZZT0

5 (Berggren *et al.*, 1999; Hassinen *et al.*, 1994; Köhler *et al.*, 1991).

Use of ATPS has so far been limited to certain targets. Due to the advantages of ATPS in protein separation, purification and localisation, highly selective and powerful methods should be developed. This is especially important for large scale processes where ATPS in

10 general is very inexpensive as a first capture step or as the only step for purification, clarification and concentration. The system should be universal so that the technique would be strong enough to mediate separation of in principle any component to the desired phase irrespective of its size or biochemical properties.

15 **Description of the invention**

In this invention we describe selective separation and partitioning of molecules and particles fusing them with targeting proteins having the capability to carry the molecule or particle of interest to the desired phase in ATPS, and to keep it in this phase if wanted. This

20 invention is directed to make ATPS usable for every biotechnological product. By addition of the targeting protein to selective products, either by genetic tagging of proteins, by chemical binding, glueing or by use of any other technique, the product molecule can be turned more suitable for separation in ATPS. Using ATPS the product or certain component is therefore driven to one phase while the other components or by-products are directed to

25 the other phase(s).

We also describe that efficient separation in ATPS can be obtained using targeting proteins which are/can be larger than the described small soluble synthetic peptide tags of 12 amino acids or less. These targeting molecules can aid in separating of small molecules but even

30 large proteins and particles. Unlike the small peptide tags, it is not necessary that they contain tryptophan residues, although they may do so. They can be hydrophobic or moderately hydrophobic and/or amphipathic in nature, either in monomeric form or when

forming aggregates. Such proteins can be found in nature or they can be designed, or obtained through for instance methods known in art for mutant generation, gene shuffling or directed evolution. Suitable targeting molecules can be screened for instance by fusion the product of interest to a library of natural or mutant sequences, and screening the ability 5 of the fusion molecules to separate in ATPS. Furthermore, any molecule capable of separating in ATPS is a suitable targeting molecule.

Several techniques exploiting purified protein for isolation of the corresponding gene may be used to find genes encoding suitable targeting molecules for ATPS. Suitable proteins or 10 polypeptides may be purified on the basis of their properties. They can be obtained by applying the cells, cell extracts or culture media to ATPS and recovering the proteins or peptides separated into the phase containing the hydrophobic phase material. Suitable targeting molecules may also be recovered for example from the culture medium foam formed either during the cultivation of a microorganism or caused by bubbling gas through 15 the medium. Proteins and peptides suitable as targeting molecules may further be recovered from aggregates caused by freezing of culture media. After the targeting molecules have been purified, the corresponding genes are isolated using techniques known to a person skilled in the art. Such techniques include for example screening of expression libraries using antibodies raised against purified polypeptide or peptide, and PCR cloning and screening of 20 genomic and/or cDNA libraries with oligonucleotides designed on the basis of N-terminal or internal protein sequences.

Examples of molecules suited as targeting proteins in ATPS found in nature are hydrophobin-like small proteins. Hydrophobins are secreted proteins with interesting 25 physico-chemical properties that have recently been discovered from filamentous fungi (Wessels, 1994; Wösten and Wessels, 1997; Kershaw and Talbot, 1998). They are usually small proteins, approximately 70 to 160 amino acids, containing eight cysteine residues in conserved pattern, and do usually not contain tryptophanes. However, also multimodular proteins with one or several hydrophobin domains and e.g. proline-rich or asparagine/glycine 30 repeats, or hydrophobins containing less than eight cysteine residues have been characterized (Lora *et al.*, 1994; Lora *et al.*, 1995; Arntz and Tudzynski, 1997). Hydrophobins have been divided into two classes based on their hydropathy profiles (Wessels, 1994).

Today most protein data exists for the hydrophobins Sc3p of *Schizophyllum commune* (class I), and cerato-ulmin of *Ophiostoma ulmi* and cryparin of *Cryponectria parasitica* (class II), although more than 30 gene sequences for hydrophobins have been published (Wösten and Wessels, 1997). HFB genes are often naturally highly expressed but due to special requirements in cultivation conditions and the biochemical properties of the proteins, purification of HFBs in large amounts have been difficult. For instance only relatively moderate production levels of a few mg per liter of Sc3 hydrophobin in static cultures are obtained (Han Wösten, personal communication). Published purification procedures include e.g. multi-step extraction from fungal cell walls using organic solvents and bubbling or freezing of culture filtrates (Wessels, 1994). No reports of successful production of hydrophobins are available; levels of cerato-ulmin were no higher than those obtained with other naturally occurring fungal isolates (Temple *et al.*, 1997).

Upon shaking hydrophobin-containing solutions, the protein monomers form rodlet-like aggregates. These structures are similar to the ones found on surfaces of aerial structures. The self-assembly of purified Sc3 hydrophobin into a 10 nm thick amphipathic layer on hydrophilic and hydrophobic surfaces has been demonstrated (Wösten *et al.*, 1994a; Wösten *et al.*, 1994b). This film is very strongly attached to the surface and not broken, for instance, by hot detergent. The hydrophobic side of the layer on hydrophilic surfaces shows properties similar to teflon (Wessels, 1994). The Sc3 assemblages, as well as those of cerato-ulmin and cryparin, also form on gas-liquid or gas-air interphases thus stabilizing air bubbles or oil droplets in water.

Surface activity of proteins is generally low but hydrophobins belong to surface-active molecules, their surfactant capacity being at least similar to traditional biosurfactants such as glycolipids, lipopetides/lipoproteins, phospholipids, neutral lipids and fatty acids (Wösten and Wessels, 1997). In fact Sc3 hydrophobin is the most potent biosurfactant known. It lowers the water surface tension to 24 mJm² at a concentration of 50 µg/ml due to a conformational change during self-assembly of monomers into an amphipathic film (Wösten and Wessels, 1997).

Hydrophobin-like molecules vary in their properties. For instance, rodlet-forming capacity has not been assigned for all hydrophobins (such as some class II), or they might have a weaker tendency to form stable aggregates (Russo *et al.*, 1992; Carpenter *et al.*, 1992). Another group of fungal amphiphatic proteins are repellents (Wösten *et al.*, 1996 (Ustilago), 5 for review, see Kershaw and Talbot, 1998). Consequently, other type of proteins suited as targeting proteins for ATPS, may have only some of the features assigned to hydrophobins. Other suitable proteins are hydrophobic ones such as e.g. lipases, cholesterol oxidase, membrane proteins, small peptide drugs like nisin, aggregating cell wall proteins, lipopeptides or any parts of these or combinations of these, and other molecules like glycolipids, 10 phospholipids, neutral lipids, fatty acids in combination with proteins or peptides.

In this invention the targeting protein, such as a hydrophobin-like protein or parts of it, is bound to the product molecule or the component to be separated. First, phase forming materials and eventually possibly also additional salts are added to a watery solution 15 containing the fusion molecule or component, and optionally also the contaminating materials. The added agents are mixed to facilitate their solubilization. As soon as they are solubilized the two phases are formed either by gravity settling or centrifugation. In the separation the target protein drives the product to for instance the detergent-rich phase which could either be the top or the bottom phase. The method is not only useful for 20 purification of products of interest but also for keeping the product or the component of interest, such as a biocatalyst, in a particular phase which enables certain useful biotechnical reactions.

Several ATPS systems are suitable for performing this invention. These include PEG 25 containing systems, detergent based systems and novel thermoseparating polymers. Detergent based systems can be nonionic, zwitterionic, anionic or kationic. The system can be based on amphiphilic polymeric detergents, micelle forming polymers. Novel polymers can be based on polyethylene-polypropylene copolymers such as pluronic block copolymers, Brij, polyoxyethylene derivatives of partial ethers of fatty acids made by adding polyoxyethylene chains to the nonesterified body and polyoxyethylene derivatives. The well known 30 PEG/salt, PEG/dextran and PEG/starch (or derivatives such as Reppal, hydroxipropyl starch) systems where PEG and water are forming the top phase and dextran/starch/salt and

water are forming the bottom phase. As salts are used phosphate, citrate, sulfate or others. In the present process the target is partitioning mainly to the top phase, while most of the contaminants are separating mainly to the bottom phase. Some hydrophobic contaminants might partition to the top phase as well. Using detergent based systems only one phase

5 forming detergent has to be added. Optionally, salts and other chemicals can be used in addition. The mentioned chemicals are added, and the solution is mixed. After mixing the separation can take place either by centrifugation or gravity settling. In order to separate into two phases the temperature of the solution has to be over the cloud-point of the detergent. The solution has to be heated if the cloud-point is not reached otherwise. If

10 wanted, a second separation step can follow after a first extraction step and the product rich phase can be further purified. Also the remaining product in the product poor and by-product rich phase can be re-extracted. Very good K values can be obtained and the yields and concentration factors are high.

15 The process of the present invention can advantageously be used in laboratory scale but is especially suitable for large scale separations. It can successfully be used in the separation of proteins and components from large fermentations. Using genetic modifications, the method can be used to purify any protein of interest including extracellular enzymes and proteins such as cellulases and hemicellulases from mixtures containing large amounts of

20 protein such as several grams per liter. Furthermore, this separation can be obtained from various culture media including industrial media containing particular materials such as cellulose and spent grain. The method can be used to purify the product from culture media of strains modified not to produce endogenous hydrophobins. The separation can be done directly from the fermentation broth which can additionally contain cells, even viscous

25 filamentous fungi. High biomass levels are acceptable for the process as explained in example 9. An example is the extracellular endoglucanase I from the fungus *Trichoderma reesei* which can be tagged for instance with the class 2 HFBI and can for example be separated with the nonionic polyoxyethylene C12-C18EO5. In this example the detergent rich phase is the lighter phase and contains most of the tagged endoglucanase while most

30 of the other cellulases, proteases and other enzymes remain in the heavier phase. The mycelium separates to the bottom phase, too. The separation can be achieved using

separation temperatures higher than 25°C. The temperature can be decreased if certain salts like NaCl or K₂SO₄ are added.

The invention describes separation of molecules produced in various different organisms

5 such as bacteria, yeast and filamentous fungi. The invention is suitable for purification of product molecules from extra- or intracellular locations, including cell wall bound molecules. It provides examples how the fusion molecule can be secreted by these different organisms but also provide an example how the fusion can be produced intracellularly.

10 The invention further describes how fusion molecules consisting of several domains can be constructed and successfully expressed and produced. The invention describes fusions of the targeting molecule to a small protein (CBD), to a moderately sized protein (EGI) and to a huge highly glycosylated protein (FloI), and different domain variations of these. These molecules can be ready as such for biotechnical use. Alternatively, the product can be

15 cleaved from the targeting protein by any method known in the art such as with proteases e.g. thrombin, factor X, papain or by chemical cleavage. Furthermore, ATPS is a preferential means to be used to separate the product from the targeting protein after cleavage, or these can be separated with other methods known in the art.

20 A surprising feature is that the targeting protein can also be used to carry large particles to the desired phase in ATPS. This can be obtained if the particles already contain proteins suited for targeting such as spores/conidia do in case of fungi. The targeting protein can also be attached to the particles or compounds *in vitro*. If cells are separated, the targeting protein can alternatively be expressed in the recombinant cells in such a way that it is

25 exposed at the cell surface whereby it mediates the separation of the cells in ATPS. A teaching how this can be done is provided in example 22. Other types of molecules which direct the targeting molecule to the cell surface can be found e.g. in the literature including bacterial outer membrane proteins and lipoproteins (Ståhl and Uhlén, 1997), and yeast proteins α -agglutinin and flocculin (Schreuder *et al.*, 1996; Klis *et al.* (1994) WO 94/01567,

30 Frenken (1994) WO 94/18330).

A further advantage of the system is that the invention combined with ATPS provides a means to separate the product or desired component not only from other unnecessary or unwanted proteins but also from harmful proteins such as proteases as described in example 6. Thus, the invention is particularly suited for production and purification of heterologous 5 proteins, e.g. sensitive mammalian proteins usually produced in limited amounts in heterologous hosts. Such proteins are for instance antibodies or fragments thereof, interferon, interleukin, oxidative enzymes and any foreign protein which can otherwise be produced in a host. It is possible that separation of the product from e.g. culture medium can also be obtained on-line or semi-continuously, thus minimising the effect of proteases 10 or other harmful components present in the culture. When produced intracellularly, the invention also provides means to separate the heterologous product, for instance the inclusion bodies it may form, from the cellular extracts.

This invention describes for the first time that fusion proteins containing hydrophobin-like 15 molecules can be made and produced in significant amounts despite the very particular properties of hydrophobin-like molecules. Importantly, this invention also describes how recombinant strains producing increased amounts of hydrophobin-like proteins as such can be made. This provides means to produce the targeting protein for uses in which it is wanted 20 that the targeting protein is bound to the product or particle *in vitro*, to enable further separation of such molecules or particles in ATPS.

Importantly, this invention also describes how hydrophobin-like molecules can be purified 25 in ATPS very efficiently with high K-values. The molecules can be separated in the same way as the above mentioned fusions, for instance by PEG systems or by detergent-based systems. Separation can be done from the culture medium or from cells. This provides a significant improvement in making pure preparations containing hydrophobin-like molecules since due to their properties their purification is very complicated and results in losses with the previously reported techniques as described above.

30 **Brief description of drawings**

Fig. 1 shows the map of the plasmid pMQ103.

5 **Fig. 2** shows the map of the plasmid pMQ113.

10 **Fig. 3** shows the map of the plasmid pMQ104.

15 **Fig. 4** shows the map of the plasmid pMQ114.

20 **Fig. 5** shows the map of the plasmid pMQ105.

25 **Fig. 6** shows the map of the plasmid pMQ115.

30 **Fig. 7** shows the map of the plasmid pMQ121.

35 **Fig. 8** Coomassie-stained 10% SDS-PAGE of the partitioning of EGIcore-HFBI fusion protein in two-phase separation using 5 % of the detergent C12-C18EO5. Lane 1, Molecular weight marker; Lane 2, Purified CBHI (4 µg); Lane 3, Purified EGI (4 µg); Lane 4, 1/10 diluted VTT-D-98691 cellulose-based culture filtrate; Lanes 5 and 6, 1/10 diluted bottom phase and detergent phase (top phase), respectively, after separation of VTT-D-98691 culture filtrate with 5% detergent; Lane 7, Non-diluted bottom phase; Lane 8, Non-diluted VTT-D-98691 cellulose culture filtrate.

40 **Fig. 9** Western analysis of the partitioning of EGIcore-HFBI fusion protein in two-phase separation by using different concentrations of the detergent C12-C18EO5. Fusion proteins were detected with anti-HFBI antibodies. Lane 1, Molecular weight marker; Lane 2, Purified EGI; Lane 3, VTT-D-98691 cellulose culture filtrate; Lanes 4 and 5, Detergent phase (top phase) and bottom phase, respectively, after separation of VTT-D-98691 culture filtrate with 5% detergent; Lane 6, Same as lane 3, except 2 % detergent was used, Lane 7, Same as lane 4, except 2 % detergent was used; Lane 8, Purified EGI; Lane 9, Purified CBHI.

5 **Fig. 10** Coomassie-stained 10% SDS-PAGE showing further purification of EGIcore-HFBI fusion protein from the endogenous CBHI when the top phase was re-extracted with 2% detergent. Lane 1, Molecular weight marker; Lane 2, Purified CBHI (4 µg); Lane 3, Purified EGI (4 µg); Lane 4, Detergent phase (top phase) after first extraction; Lane 5, Detergent phase (top phase) after second extraction.

10 **Fig. 11** Coomassie-stained 10% SDS-PAGE analysis of the EGI-HFBI protein when treated with thrombin. Lane 1, Molecular weight marker; Lane 2, EGI-HFBI (1 mg/ml) treated 72 h with 3 U of thrombin at 24°C; Lane 3, Same as lane 2, except no thrombin was added; Lane 4, EGI-HFBI (1 mg/ml) treated 48 h with 9 U of thrombin at 36°C; Lane 5, Same as lane 4, except no thrombin was added; Lane 6, Same as lane 5, except no incubation at 36°C.

15 **Fig. 12** shows the map of the plasmid pTNS13.

20 **Fig. 13** Western analysis of the partitioning of dCBD-HFBI fusion protein in two-phase separation using 5 % of the detergent C12-C18EO5. Fusion protein was detected with anti-HFBI antibody. Lane 1, Four times concentrated culture filtrate; Lane 2, Four times concentrated bottom phase; Lane 3, Top phase.

25 **Fig. 14** shows the map of the plasmid pTNS15. A non-functional restriction site is indicated with an asterisk.

Fig. 15 shows the map of the plasmid pTNS18.

Fig. 16 shows the map of the plasmid pTNS23.

30 **Fig. 17** shows that separation to the detergent phase of cells expressing a hydrophobin on cell surface occurs: the top detergent phase of *S. cerevisiae* VTT-C-99315 is turbid, whereas the top detergent phase of the control strain H2155 is clear.

Fig. 18 shows the map of the plasmid pTNS32.

Fig. 19 shows the map of the plasmid pTH4.

5 **Fig. 20** shows the map of the plasmid pTNS30.

Fig. 21 shows the map of the plasmid pTH1.

10 **Fig. 22** shows the map of the plasmid pTH2.

Fig. 23 shows the map of the plasmid pKS2.

Fig. 24 SDS gel showing the purification of HFBI-dCBD in a Berol 532 ATPS system.

15 **Fig. 25** Western analysis of the partitioning of HFBI-ENA5ScFv fusion protein in two-phase separation using 4% of the detergent C12-C18EO5. Lanes from left. (1) Molecular weight marker, (2) Top (enriched) phase of the strain VTT-D-00791, (3) Bottom (depleted) phase of the strain VTT-D-00791.

20 **Fig. 26** Western analysis of the partitioning of SC3 hydrophobin using SC3 specific antibodies. Lane 1, Bottom phase of the strain VTT-D-00792, Lane 2, Top phase of the strain VTT-D-00792.

25 **Fig. 27** HPLC analysis for monitoring of the partitioning of HFBI in 2% Berol 532.

Fig. 28 HPLC analysis for monitoring of the partitioning of HFBII in 2% Berol 532.

The invention is further illustrated by the following Examples which describe construction of the fusion molecules of the invention, and partitioning of the molecules of interest using 30 the process according to the invention.

EXAMPLES**Example 1**

Construction of vectors for expression of EGI and EGIcore HFBI fusion proteins
5 **under the *cbh1* and *gpd1* promoters of *Trichoderma* and *gpdA* promoter of *Aspergillus***

For construction of an EGI-HFBI fusion protein, *hfb1* (SEQ ID 1) coding region (from Ser-23 to the STOP codon) and a peptide linker (Val Pro Arg Gly Ser Ser Ser Gly Thr Ala Pro Gly Gly) preceding it was amplified with PCR using pTNS9 as a template and as a 5' primer

10 **TCG GG C ACT ACG TG C CAG TAT AGC AAC GAC TAC TAC TCG CAA TGC**
CTT GTT CCG CGT GGC TCT AGT TCT GGA ACC GCA (SEQ ID 2) and as a 3' primer
TCG TAC GGA TCC TCA AGC ACC GAC GGC GGT (SEQ ID 3). pTNS9 has been
described in detail in Example 19. The sequence in bold in the 5' primer encodes 16 C-terminal
15 residues of EGI. The sequence in italics is a thrombin cleavage site and the underlined
CACTACGTG is a DraIII site. The underlined GGATCC in the 3' primer is a BamHI site.
The 280 bp PCR fragment was purified from agarose gel and ligated to pGEM-T T/A vector
(Promega) resulting in pMQ102.

For construction of an EGIcore-HFBI fusion protein, the *hfb1* coding region (as above) was
20 amplified with PCR using pTNS9 as a template and as a 5' primer **ACT ACA CGG AG G**
AGC TC G ACG ACT TCG AGC AGC CCG AGC TGC ACG CAG AGC AAC GGC
AAC GGC (SEQ ID 4) and as a 3' primer SEQ ID 3. The sequence in bold in the 5' primer
encodes amino acids 410-425 in EGI and the underlined GAGCTC is a SacI site. The 260 bp
PCR fragment was purified from agarose gel and ligated to pPCRII T/A vector (Invitrogen)
25 resulting in pMQ111.

In the next step *Trichoderma* expression vectors for production of EGI-HFBI and EGIcore-HFBI fusion proteins under the control of *cbh1* promoter and terminator sequences were constructed. The expression vector used as a backbone in the constructs is pPLE3 (Nakari *et al.* (1994) WO 94/04673) which contains a pUC18 backbone, and carries the *cbh1* promoter (SEQ ID 5) inserted at the EcoRI site. The *cbh1* promoter is operably linked to the full length *egl1* cDNA (SEQ ID 6) coding sequence and to the *cbh1* transcriptional terminator (SEQ ID

7). The plasmid pMQ102 was digested with DraIII and BamHI and the released 280 bp fragment containing *hfb1* and linker sequences was purified from agarose gel and ligated to pPLE3 digested with DraIII and BamHI. The plasmid pMQ111 was digested with SacI and BamHI and the 260 bp fragment containing the *hfb1* sequence was ligated to pPLE3 digested 5 with SacI and BamHI. The resulting plasmids pMQ103 (Figure 1) and pMQ113 (Figure 2) carry the coding sequences for full-length EGI linked to HFBI via a peptide linker and for EGICore linked to HFBI via its own linker region, respectively, under the control of *cbl1* promoter and terminator sequences.

10 *Trichoderma* expression vectors for production of EGI-HFBI and EGICore-HFBI fusion proteins under the control of *gpd1* promoter and terminator sequences of *Trichoderma* and *gpd4* promoter and *trpC* terminator sequences of *Aspergillus* were constructed as follows. A SacII site was inserted inbetween the XbaI and PacI sites of pMV4 using as an adapter annealed primers TAA CCG CGG T (SEQ ID 8) and CTA GAC CGC GGT TAA T (SEQ 15 ID 9). The resulting plasmid is pMVQ. pMV4 contains a pNEB193 (New England Biolabs) backbone, and carries a 1.2 kb *Trichoderma gpd1* promoter (SEQ ID 10) and a 1.1 kb *gpd1* terminator (SEQ ID 11) inserted at Sall-XbaI and BamHI-Asci sites, respectively. The expression cassettes for EGI-HFBI and EGICore-HFBI were released from pMQ103 and pMQ113 with SacII and BamHI, purified from agarose gel and ligated to pMVQ cut with 20 SacII and BamHI. The resulting plasmids pMQ104 (Figure 3) and pMQ114 (Figure 4) carry the EGI-HFBI and EGICore-HFBI cassettes, respectively, under the control of *Trichoderma gpd1* transcriptional control sequences. Expression plasmids pMQ105 (Figure 5) and pMQ115 (Figure 6) containing EGI-HFBI and EGICore-HFBI cassettes, respectively, operably linked to the *gpd4* promoter and *trpC* terminator of *Aspergillus* were constructed. 25 EGI-HFBI and EGICore-HFBI cassettes were released from plasmids pMQ104 and pMQ114 with XbaI and BamHI, blunted with T4 DNA polymerase and ligated to NcoI digested and T4 DNA polymerase treated pAN52-1 (SEQ ID 12). pAN52-1 contains a pUC18 backbone, and carries a 2.3 kb *gpd4* promoter and a 0.7 kb *trpC* terminator sequences of *A. nidulans*.

Example 2**Construction of vectors for over-production of HFBI on cellulase-inducing and -repressing media**

5 For over-expression of HFBI under *cbh1* promoter the protein coding region of *hfb1* was amplified with PCR using as a template pEA10 (Nakari-Setälä *et al.*, 1996). pEA10 carries a 5.8 kb genomic Sall fragment containing *hfb1* coding and flanking sequences. **GTC AA C CGC GG A CTG CGC ATC ATG AAG TTC TTC GCC ATC** (SEQ ID 13) was used as a 5' primer in the PCR and as a 3' primer SEQ ID 3. The sequence in bold in the 5' primer is

10 21 bp of *cbh1* promoter adjacent to translational start site of the corresponding gene and the underlined CCGCGG is a KspI site. The obtained fragment of 430 bp was digested with KspI and BamHI and ligated to pMQ103 digested with KspI and BamHI. The resulting plasmid pMQ121 (Figure 7) carries the coding sequence of *hfb1* operably linked to *cbh1* transcriptional control sequences. pEA10 plasmid is used for over-production of HFBI in

15 cellulase-repressing conditions.

Example 3**Transformation of *Trichoderma* and purification of the EGI-HFBI and EGIcore-HFBI producing and HFBI over-producing clones**

20 *Trichoderma reesei* strains QM9414 (VTT-D-74075) and Rut-C30 (VTT-D-86271) were co-transformed essentially as described (Penttilä *et al.*, 1987) using 3-13 µg of the plasmids pMQ103, pMQ113, pMQ104, pMQ114, pMQ105, pMQ115, pMQ121 and pEA10 and as the selection plasmids 1-3 µg pToC202, p3SR2 or pARO21. pToC202 (pUC19 backbone) and p3SR2 (pBR322 backbone) plasmids carry 2.7 kb XbaI and 5 kb EcoRI-Sall genomic fragments of *A. nidulans*, respectively, containing the *amdS* gene (Hynes *et al.*, 1983; Tilburn *et al.*, 1983). pARO21 is essentially the same as pRLMex30 (Mach *et al.* 1994) and carries the *E. coli* *hph* gene operably linked to 730 bp of *pki1* promoter and 1 kb of *cbh2* terminator sequences of *T. reesei*. The Amd⁺ and Hyg⁺ transformants obtained were streaked three

25 times onto plates containing acetamide and hygromycin, respectively (Penttilä *et al.*, 1987). Thereafter spore suspensions were made from transformants grown on Potato Dextrose agar (Difco).

30

The production of the fusion proteins EGI-HFBI and EGIcore-HFBI and HFBI was tested by slot blotting or Western analysis with EGI and HFBI specific antibodies from shake flask or microtiter plate cultivations carried out in minimal medium supplemented with either glucose,

5 lactose or a mixture of Solka flock cellulose and/or spent grain and/or whey. The spore suspensions of the fusion protein producing clones were purified to single spore cultures on selection plates (containing either acetamide or hygromycin). To determine the best producers, production of the fusion proteins was analyzed again from these purified clones as described above.

10

T. reesei strains selected for further fermentor cultivations are VTT-D-98692 (pEA10), VTT-D-98492 (pMQ121), VTT-D-98693 (pMQ103), VTT-D-98691 (pMQ113), VTT-D-98681 (pMQ105) and VTT-D-98682 (pMQ115). These strains have QM9414 as the host strain. VTT-D-99702 (pMQ113) has Rut-C30 as the host strain.

15

Example 4

Cultivation of the EGI-HFBI and EGIcore-HFBI protein producing and HFBI over-producing *Trichoderma* strains

20 EGI-HFBI and EGIcore-HFBI fusions were produced under the *cbbI* promoter in a 15-litre fermenter using *T. reesei* strains VTT-D-98693 (pMQ103) and VTT-D-98691 (pMQ113), respectively. Strains were grown 5 days on minimal medium (Penttilä *et al.*, 1987) containing 4% Solka flock cellulose (James River Corporation, Berlin, NH) and 2 % spent grain (Primalco, Koskenkorva, Finland). EGIcore-HFBI was also produced in fermenter (15 l) 25 using the Rut-C30 strain VTT-D-99702 (pMQ113) with 4 % lactose medium. To induce the production of EGI-HFBI and EGIcore-HFBI fusions under *Aspergillus gpdA* promoter, *T. reesei* strains VTT-D-98681 (pMQ105) and VTT-D-98682 (pMQ115) were cultivated in 15-litre fermenter. Strains were grown 3 to 5 days on minimal medium supplemented with 2% glucose, 0.2% Peptone, and 0.1% Yeast Extract, and with glucose feed to maintain the 30 glucose concentration in the range of 1 to 3% throughout the cultivation. HFBI over-producing strain VTT-D-98692 (pEA10) was grown similarly in 15 l on glucose medium and the strain VTT-D-98492 (pQM121) over-producing HFBI under *cbbI* promoter was

cultivated for 7 days in 15-litre fermentor on medium containing 4% Solka flock and 2% spent grain. The control cultivations with the host strains of the transformants, QM9414 (VTT-D-74075) and Rut-C30 (VTT-D-86271), were carried out on media containing i) Solka flock cellulose and either spent grain or whey, ii) lactose and iii) glucose similarly as 5 described above.

When proper some *T. reesei* transformant strains and their host strains were also cultivated at 28°C in shake flasks for 5 to 6 days in 50 to 150 ml volume of *Trichoderma* minimal medium (Penttilä *et al.*, 1987) supplemented with either 3% Solka flock cellulose and 1% spent grain or 10 3-4% glucose with glucose feeding.

Example 5

Standard separation assays and analysis

15 If not otherwise stated the standard ATPS and subsequent analyses and calculations were carried out as explained in this example.

In general whole fermentation broth, supernatant (biomass separated by centrifugation or 20 filtration) or purified proteins in buffer were separated in 10 ml graduated tubes. First detergent was added into the tubes and the tubes were then filled to 10 mg with protein containing liquid. The amount of detergent in the tube was calculated in weight percent of detergents. After thorough mixing in an overhead shaker the separation took place by either gravity settling in a water bath at constant temperature or by centrifugation at constant 25 temperature. The separation usually was performed at 30°C, the standard amount of detergent used was 2-5% (w/v). After separation the volume ratio was noted and samples were taken from the lighter and heavier phase for analysis.

Two-phase separations were analysed qualitatively by using SDS-PAGE gels followed by 30 visualization of the fusion proteins with Coomassie brilliant blue R-250 (Sigma) or Western blotting. Polyclonal anti-HFBI antibody were used in Western analysis for detection of EGIcore-HFBI, EGI-HFBI and dCBD-HFBI proteins together with alkaline phosphatase conjugated anti-rabbit IgG (Bio-Rad) Alkaline phosphatase activity was detected

colorimetrically with BCIP (5-bromo-4-chloro-3-indolyl-phosphate) used in conjunction with NBT (nitro blue tetrazolium) (Promega).

Contaminating endogenous EGI, CBHI and EGIII in the top phase was tested with appropriate antibodies. Acidic protease activity in the top and bottom phase was also tested using the SAP method (Food Chemicals Codex, p. 496-497, 1981), which is based on the 30 min enzymatic hydrolysis of a hemoglobin substrate. All reactions were performed at pH 4.7 and 40 °C. Unhydrolyzed substrate was precipitated with 14% TCA and removed by filtration. The released tyrosine and tryptophan was determined spectrophotometrically. Total protein concentrations were determined by *Non-Interfering Protein Assay*™ (Geno Technology, Inc).

EGI activity was detected using 4-methylumbelliferyl- β -D-cellobioside (MUC) (Sigma M 6018) as substrate (Van Tilbeurgh H. & Caeyssens M., 1985; Van Tilbeurgh *et.al.*, 1982). EGI hydrolyses the β -glycosidic bond and fluorogenic 4-methylumbellifrone is released, which can be measured using a fluorometer equipped with a 360 excitation filter and a 455 nm emission filter. CBHI also hydrolyses the substrate and it was inhibited by addition of cellobiose (C-7252, Sigma). EGI containing liquid was added in an appropriate dilution to a buffer containing 50 mM sodium acetate buffer (pH 5), 0.6 mM MUC and 4.6 mM cellobiose. The mixture was heated to 50°C. The reaction was stopped after ten minutes using 2% Na₂CO₃, pH 10. Purified CBHI was detected using the same assay as for EGI without the addition of the inhibitor cellobiose.

The partition coefficient K was defined as the ratio of the measured concentrations or activities in the top and bottom phase, respectively.

The Yield Y was defined as follows:

$$Y_T = \frac{1}{1 + \left[\frac{V_B}{V_T} \cdot \frac{1}{K} \right]}$$

where Y_T is the Yield of the top phase, V_B and V_T are the volumes of top and bottom phase, respectively. The Yield of the bottom phase can be described accordingly

The mass balances, e.g. recovery of all added protein, were always checked for completeness to ensure no artificially high Yield (e.g. due to possible inactivation of the protein in the bottom phase). The values were usually calculated based on total enzyme activity (EGI wt plus the EGI-fusion) and thus the values are underestimated for the separation of the fusion as 5 demonstrated in Example 16.

Example 6

Small scale ATPS separation studies and gel analysis

10 EGI-HFBI and EGIcore-HFBI fusions produced under the *cblh1* promoter in a 15-litre fermenter on Solka flock cellulose and spent grain medium as described in Example 4 using *T. reesei* strains VTT-D-98693 (pMQ103) and VTT-D-98691 (pMQ113), respectively, were separated in small scale ATPS as described above.

15 The phases from the two phase separations were analysed qualitatively by using SDS-PAGE gels followed by visualization of the fusion proteins with Coomassie brilliant blue or Western blotting. Coomassie stained SDS-PAGE (10%) is shown in Figure 8. In the lane containing the non-extracted culture filtrate three distinct closely migrating bands can be seen (the sample was diluted 1/10 with H₂O). The topmost band is CBHI, the band in the middle is 20 EGIcore-HFBI fusion and the lower one endogenous EGI. In the samples separated in ATPS, only two bands (CBHI and EGI) are seen in the sample from bottom phase and one band representing EGIcore-HFBI in the sample obtained from the top phase.

25 Western blotting with HFBI antibody showed thick bands for the top phase, whereas for the bottom phase there was only faint band demonstrating that the fusion is separating strongly into the detergent top phase. Figure 9 shows the separation of the EGIcore-HFBI fusion produced on cellulose media into the top phase. Contaminating endogenous EGI and EGIII in the top phase was tested with appropriate antibodies but no signal was detected.

30 Small amount of endogenous CBHI was found in the upper phase when CBHI antibody was used in Western blotting. EGI, EGIII and proteases were not found in the top phase. Further purification from the contaminating CBHI was observed when the top phase was re-extracted

with 2 % detergent. The Figure 10 shows that the upper phase does not any more contain CBHI and pure fusion protein is recovered.

EGIcore-HFBI was also produced in fermenter (15 l) using the Rut-C30 strain VTT-D-99702 (pMQ113) with 4 % lactose medium. The separation in ATPS carried out in the standard manner gave essentially the same result as the separation from cellulose containing medium thus demonstrating that the purification can be carried out from several media relevant for large scale industrial use.

10 Acidic protease activity in the top was only 1/15 compared to the bottom phase (table below) demonstrating that acidic proteases remain in the bottom phase.

	A (275 nm)	HUT ³ /ml
Bottom phase ¹	0.146	41.6
Top phase ²	0.009	2.6

¹1/10 diluted bottom phase after separation of VTT-D-98691 culture filtrate with 2% detergent

15 ²1/100 diluted bottom phase after separation of VTT-D-98691 culture filtrate with 2% detergent

³1 HUT = enzyme concentration, which in reaction conditions hydrolyses hemoglobin in 1 min so that the absorbance at 275 nm of the formed hydrolysate equals 1.10 µg tyrosine/ml 0.006 N HCl solution.

These results show that the fusion protein can be purified extremely efficiently and the 20 resulting preparate is free of other proteins produced by the fungus including proteases.

Example 7

Recovery of the native EGI in ATPS after thrombin cleavage

25 EGI-HFBI protein produced by the strain VTT-D-98693 has a thrombin cleavage site (LVPRGS) designed in the linker region between the EGI CBD and HFBI, which would enable the recovery of the native EGI after thrombin cleavage. EGI-HFBI fusion protein was purified from the culture filtrate (100 ml) of strain VTT-D-98693 grown on 4% Solka flock

cellulose and 2 % spent grain as described in Example 4 using the 2-phase separation system (5 % detergent). After removal of the bottom phase the detergent phase was extracted by isobutanol. The resulting water phase (~19 ml) was divided in eppendorf tubes and the liquid was evaporated with speed vac. Remaining lyophilizate was diluted to 50 mM Tris-Cl (pH 8).

5 To test the efficiency of thrombin cleavage, 9 units of thrombin (Sigma) was incubated > 24 h with 1 mg EGI-HFBI fusion protein in 36 °C at pH 8.0. Coomassie stained SDS-PAGE (10 %) was used for detection.

Only minor cleavage was observed in 48 h under these conditions (Figure 11), possibly due to
10 steric hindrance by O-glycosylation in the linker.

Example 8

Separation of low concentrations of EGIcore-HFBI in ATPS

15 Detergent based aqueous two-phase systems were successfully applied using very low concentrations (diluted) of EGIcore-HFBI fusion protein produced with the *cbhI* promoter in *T. reesei* VTT-D-98691 (pMQ 113) from a 15 liter cultivation carried out on Solka flock cellulose with spent grain as described in Example 4.

20 The original protein concentration of the supernatant was 7.0 mg/ml. This supernatant was diluted with de-ionised water by a factor of 100 and 1000, respectively. The fusion protein could be separated using 2% (w/w) of the detergent C12-C18EO5 with partitioning coefficients higher than 5. This is shown in the table below together with the experiment with non-diluted supernatant. The partitioning coefficients were calculated based on activity
25 measurements for total EGI (wild type and fusion protein together).

	EGIcore-HFBI non-diluted supernatant	dilution 1/100	dilution 1/1000
K	4.1	5.3	5.6
Y [%]	38	31	32

Example 9**Separation of EGIcore-HFBI from fungal biomass containing culture broths**

EGIcore-HFBI from *T.reesei* strain VTT-D-98691 (pMQ 113-2) was cultivated (50 ml in 5 250 ml shake flasks) on Solka flock cellulose with spent grain as described in Example 4. Directly after the cultivation, part of the whole broth was centrifuged at 3000 rpm for 30 min, supernatant was spilled out and the centrifuged mycelium was added to the supernatant to obtain artificial whole broths containing different amounts of biomass.

10 Using 5% of C12-C18EO5 in a 10 g experiment consisting of up to 50% wet biomass (weight of wet biomass divided by the sum of wet biomass and supernatant) could still be separated without any difficulties. The Yield remained in between 61 and 64 % and therefore it is not significantly different in comparison to the experiment carried out with supernatant only (without mycelium) (see table below). The total recovery of the fusion protein is even 15 higher. This is most probably due to cell attached enzyme extracted in the ATPS increasing the total amount of EGI. The partitioning coefficient was calculated based on activity measurements for total EGI (wild type and fusion protein together).

	K	Y[%]
Supernatant	5.5	62
25% of wet biomass in supernatant	7.3	66
40% of wet biomass in supernatant	6.4	61
50% of wet biomass in supernatant	7.6	64

Example 10**Separation of EGI-HFBI in ATPS**

EGI-HFBI from *Trichoderma reesei* strain VTT-D-98693 (pMQ 103) from a 15 liter cultivation carried out on Solka flock cellulose and spent grain as described in Example 4 was separated in a 10 g experiment using different amounts of C12-C18EO5. The partitioning coefficients are shown below. The partitioning coefficient was calculated based on activity measurements for total EGI (wild type and fusion protein together), and as in previous examples the endogenous EGI is included in the partitioning coefficients.

10

Detergent [% w/w]	2	3	5	7
K	1.9	1.8	1.4	1.1

Example 11**Separation of EGICore-HFBI in 50 ml**

15

EGICore-HFBI from *T. reesei* strain VTT-D-98691 (pMQ 113) cultivated in 15 liters using Solka flock cellulose and spent grain as described in Example 4 was separated in Falcon tubes in a 50 g experiment using 5% of C12-C18EO5. A partition coefficient of 2.52 and a yield of 51 % could be obtained. The separation was performed at 30°C at 3000rpm for 30 minutes. 20 The values are based on activity measurements for total EGI activity (wild type and fusion protein together) including endogenous EGI.

Example 12**Separation of EGICore-HFBI in ATPS using different detergents**

25

EGICore-HFBI from *T. reesei* strain VTT-D-98691 (pMQ 113) cultivated in 15 liters using Solka flock cellulose with spent grain as described in Example 4 was separated in a 10 g experiment using 2% of detergent in each experiment. The detergents investigated in this example were C10 EO5, C12 EO5, C14 EO6 (each Nikko Chemicals, Japan), C12-C18 EO5

(„Agrimul NRE 1205“, Henkel, Germany), C12/14 5EO, C12/14 6EO (Clariant, Germany), C9/11 EO5.5 („Berrol 266“, Akzo Nobel, Germany), Triton X-114 (Sigma, Germany). The partition coefficients and yields are listed below. The values are based on activity measurements for total EGI activity (wild type and fusion protein together) including 5 endogenous EGI.

	K	Y(fusion) [%]
C10EO5	20	56
C12EO5	15	57
C12-C18EO5	14	66
C12/14 5EO	12	58
C12/14 6EO	14	62
C14EO6	11	54
C9/11 EO5.5	5	30
Triton X-114	0.16	53

10 Example 13

Separation of EGIcore-HFBI in ATPS from glucose grown cultures

EGIcore-HFBI was separated from cultivation of the *Trichoderma reesei* strain VTT-D-98682 (pMQ115) cultivated with glucose as described in Example 4. The supernatant was 15 separated with 2% of the detergent C12-C18 EO5. The fusion protein could be partitioned with a K value of 2.4. In comparison, the K value for the native EGI is 0.3 when measured in a similar way for purified EGI.

Example 14

20 Separation of EGIcore-HFBI using different concentrations of detergent

EGIcore-HFBI from *T. reesei* VTT-D-98691 (pMQ 113) cultivated in 15 litres using Solka flock with spent grain as described in Example 4 was separated in detergent based ATPS

applying different amounts of the detergent C12-C18 EO5 on the cell free supernatant. The partitioning coefficients are shown in the table below. The corresponding gel electrophoresis and Western antibody-blots are shown in Figure 8 and Figure 9, respectively.

The values are based on activity measurements of total EGI activity.

5

Amount of detergent C12-C18 EO5	K	Yield(%)
1.0%	6.1	9
2.0%	4.1	38
3.5%	3.6	50
5.0%	2.9	55
7.5%	1.7	53
10.0%	1.1	58

Example 15

Re-extraction of the detergent phase

10

Detergent based ATPS was applied on EGIcore-HFBI fusion protein containing supernatant produced by the strain VTT-D-98691 (pMQ 113) in a shake flask cultivation. The first extraction using C12-C18EO5 conducted under the standard conditions shows a partitioning coefficient of 16 and a yield of 72 % (wild type EGI measured together with fusion protein).

15

The top phase was re-extracted in 10 mM sodium acetate buffer (pH 5) with 2% of detergent. A partitioning coefficient of 52 and a yield of 89 % could be obtained. In the re-extraction experiment of the bottom phase (2% of detergent), a small yield of 7.5% and a K of 0.8 of EGI activity were achieved. The partitioning coefficients were calculated based on activity measurements for total EGI (wild type and fusion protein together). Due to the wild

20

type EGI present in the sample, the yield is at least 72% and the partitioning coefficient at least 16 in the first extraction. The SDS-PAGE results of both extraxtions are shown in Figure 10.

Separation step	K	Y[%]
2% detergent	16	72
reextraction top phase	52	89
reextraction bottom phase	0.8	7.5

Example 16

Separation of pure cellulases in ATPS

5

The effect of HFBI on partitioning and the final yield can further be demonstrated by comparing the extraction result of EGIcore-HFB fusion with extraction results obtained with purified wild type EGI and EGIcore. The fusion protein is partitioning more than 100 times better to the detergent phase (see table below).

10

The improvement on the partitioning of the purified fusion protein from the first extraction obtained in the re-extraction (see Example 15) can be explained by the partitioning of the wild type EGI as demonstrated with purified wild type EGI in the table below. The wild type EGI lowers the partitioning coefficient in the first extraction (since EGI activity is measured from both top and bottom phase), but the absence of it in the re-extraction increases the partitioning coefficient of the EGIcore-HFBI fusion. The purity can in addition be demonstrated by analysing the partitioning of pure CBHI, which is the major contaminating protein corresponding to about 50 % of all secreted *T. reesei* proteins. Pure CBHI has a partitioning coefficient of 0.5 and a yield of 3.6 and is therefore separated from the fusion protein.

15

20

Separation step	K	Y[%]
re-extraction of top phase	52	89
extraction of pure wild type EGI	0.3	2.2
extraction of pure EGI-core	0.3	2.3
extraction of pure CBHI	0.5	3.6

Using the definitions of K and Y and calculating mass balances, the ratio of the amount of EGI fusion protein to EGI wild type can be calculated. The "true" partition coefficients and Yields can be concluded from this. "True" means the values which would be detected if it would be possible to measure only the amount of EGI-fusion without measuring the amount 5 for EGI wild type at the same time.

The fundament for the calculation is the re-extraction experiment. The re-extracted top phase is believed to be pure. An example of the measured values and the calculated "true" values based on this are shown in the table below for two cultivations of VTT-D-98691 (pMQ113) 10 grown as described in Example 4.

cultivation vessel	cultivation substrate	K "with EGI wt"	"true" K	Y [%] "with EGI wt"	"true" Y [%]
15 liter fermenter	whey permeate	4	6	16	54
250 ml shake flask	cellulose	16	54	66	90

15 **Example 17**

HFBI and HFBII purification in ATPS

HFBI was produced by cultivating the *T. reesei* strain VTT-D-98692 (pEA10-103B) using glucose as substrate as described in Example 4. HFBI could be separated using 2% of the 20 detergent C12-C18 EO5 with a partition coefficient higher than 20 under the standard conditions described.

HFBII was produced by cultivating the *T. reesei* strain VTT-D-74075 (QM9414) on whey spent grain as described in Example 4. HFBII could be separated using 2% of the detergent 25 C12-C18 EO5, exceeding a partition coefficient of 10 under the standard conditions.

Both HFBI and HFBII hydrophobins are thus partitioning well to the upper phase in ATPS.

Example 18**Detergent based ATPS with additional NaCl**

EGIcore-HFBI from which cultivation of *T. reesei* was separated in a 10 g experiment using 5% of C12-C18EO5. The partitioning coefficient of the supernatant was 3.5 with a volume ratio of 0.2. Using 1.1 % (w/v) NaCl the partitioning coefficient could be increased to 4.3 with a lower volume ratio of 0.14.

Example 19

10 **Construction of an *E. coli* strain expressing a fusion protein HFBI-dCBD, containing hydrophobin I and double cellulose binding (CBD) domains**

A 280 bp DNA fragment containing a modified *cbbh2* linker region followed by the coding region of *hfb1* from Ser-23 to the STOP codon was amplified by PCR using the plasmid 15 pARO1 (Nakari-Setälä *et al.*, 1996) as a template. The 5' primer was 5' TCT AGC AAG CTT GGC TCT AGT TCT GGA ACC GCA CCA **GGC GGC AGC AAC GGC AAC** GGC AAT GTT TGC (SEQ ID 14) and the 3' primer was 5' TCG TAC AAG CTT TCA AGC ACC GAC GGC GGT (SEQ ID 15). The sequences in bold in the 5' and 3' primers encode the modified CBHII linker (Gly Ser Ser Ser Gly Thr Ala Pro Gly Gly) and a 20 translational STOP, respectively, and the underlined AAGCTT in both primers is a HindIII site. The PCR fragment was purified from agarose gel, digested with HindIII and ligated to HindIII digested and SAP treated (Shrimp Alkaline Phosphatase, USB) pSP73 resulting in plasmid pTNS9.

25 For subsequent cloning of the modified CBHII linker-HFBI fragment to an *E. coli* expression vector, pTNS9 was digested with HindIII and the proper fragment was purified from agarose gel. This HindIII fragment was cloned to HindIII digested and SAP treated (Shrimp Alkaline Phosphatase, USB) B599 resulting in pTNS13 (Figure 12). The *E. coli* expression vector B599 is essentially the same as the one described by Linder *et al.* (1996) except that it is 30 missing a STOP codon at the end of the protein coding sequence. It carries the coding sequence for a fusion protein containing CBHII CBD (41 N-terminal residues of CBHII) and CBHI CBD linked together via CBHI linker region (CBHI linker and CBD are the last 57

residues in CBHI). The expression and secretion of the fusion protein in B599 is under the control of *tac* promoter and *peb* signal sequence (Takkinen *et al.*, (1991). pTNS13 expression vector thus carries the coding region for a fusion protein of double CBD and HFBI linked in frame via the Gly-Ser-Ser-Ser-Gly-Thr-Ala-Pro-Gly-Gly peptide. This vector also contains 5 the *amp* gene for selection of *E. coli* transformants. pTNS13 plasmid was transformed into *E. coli* strain RV308 (su-, Δ lacX74, *galSII*::OP308, *strA*) and this strain was used for production of the fusion protein.

Example 20

10 Separation of HFBI-dCDB molecules expressed in *E. coli* in A TPS

dCBD-HFBI was produced in *E. coli* strain RV 308 transformed with pTNS13 plasmid as described above. The inoculum of RV308/pTNS13 was grown to the exponential growth phase in LB medium containing ampicillin (0.1 g/l) and 1% glucose. Fermentation was carried 15 out using mineral salt medium described by Pack *et al.* (1993) with glucose (feed) in 10 litre fermenter. During cultivation temperature was maintained at 28 °C and pH was controlled at 6.8 with NH₄OH. Cell growth was monitored by measuring OD₆₀₀ and dry weight of biomass. The culture was induced with 50 μ M (final concentration) IPTG (isopropyl- β -D-thiogalactopyranoside) at late-exponential growth phase (OD₆₀₀=50-60) to promote fusion 20 protein production.

Two-phase separation analysis of dCBD-HFBI protein was performed using culture filtrate and 5% detergent in the total volume of 40 ml. Results from Western blotting showed that 2-phase separation with 5 % detergent in the standard way was highly specific also for the 25 dCBD-HFBI fusion. Strong signal was observed in the sample from the detergent phase compared to the sample from the bottom phase as shown in Figure 13.

Example 21**Construction of yeast strains expressing HFBI-Flo1 fusion protein on the cell surface**

For construction of a HFBI-FLO1 fusion protein expression cassette, *hfb1* (SEQ ID 1) 5 coding region (from Ser-23 to the STOP codon) was amplified with PCR using pARO1 (Nakari-Setälä *et al.*, 1996) as a template and as a 5' primer TCT AGC TCT AGA AGC AAC GGC AAC GGC AAT GTT (SEQ ID 16) and as a 3' primer TGC TAG TCG ACC TGC TAG CAG CAC CGA CGG CGG TCT G (SEQ ID 17). The underlined sequences in the 5' and 3' primers are XbaI and NheI sites, respectively. The 0.225 bp PCR fragment was 10 purified from agarose gel and ligated to pGEM-T vector (Promega) resulting in pTNS10. The *hfb1* fragment was released from pTNS10 with XbaI and NheI and ligated to pTNS15 cut with the same restriction enzymes. Plasmid pTNS15 (Figure 14) is essentially the same as 15 plasmid pBR-ADH1-FLO1L by Watari *et al.* 1994 except that a NheI site in the pBR322 backbone has been replaced by a BglII site and a unique XbaI site is introduced by linker cloning in the unique AocI site preceding the putative signal sequence cleavage site. The resulting plasmid pTNS18 (Figure 15) contains the complete expression cassette for HFBI-FLO1 fusion protein in which HFBI substitutes the putative lectin domain from Ser-26 to Ser-319 in the yeast flocculin FLO1 (SEQ ID 18).
20 In the next step, yeast expression vector for production of HFBI-FLO1 fusion protein was constructed. The expression vector used as a backbone in the construct is pYES2 (Invitrogen) (SEQ ID 19) which is a high-copy episomal vector designed for inducible expression of recombinant proteins in *S. cerevisiae*. It carries *GAL1* promoter and *CYC1* terminator sequences which regulate transcription, and 2 μ origin of replication and *URA3* 25 gene for maintenance and selection in the host strain. The plasmid pTNS18 was digested with HindIII and the released 3.95 kb fragment containing the expression cassette for HFBI-FLO1 was purified from agarose gel and ligated to pYES2 digested with HindIII. This ligation mixture was concentrated by standard ethanol precipitation. The ligation mixture should contain besides unligated fragments and uncorrect ligation products also molecules where the 30 vector and insert are correctly ligated with each other to result in plasmid pTNS23 (Fig. 16) which carries the expression cassette for HFBI-FLO1 operably linked to *GAL1* and *CYC1* terminator sequences.

The above ligation mixture was transformed using the LiAc method of Gietz *et al.* (1992) into a laboratory *S. cerevisiae* strain H452 (wild type W303-1A; Thomas and Rothstein, 1989). Transformant colonies able to grow on SC-URA plates were picked and streaked on 5 selective plates. Nitrocellulose replicas were taken from the plates and treated for colony hybridization according to Sherman *et al.* (1983). To find those yeast colonies containing the pTNS23 plasmid, replicas were hybridized with digoxigenin labelled *hfb1* coding fragment after which an immunological detection was performed all according to the manufacturer (Boehringer Mannheim). Plasmids were recovered from several yeast colonies giving positive 10 hybridization signal by isolating total DNA and using this in electroporation of *E. coli*. Restriction mapping and sequencing were carried out to confirm that the pTNS23 plasmid in the yeast transformants was correct. One of the transformants carrying plasmid pTNS23 was chosen for further studies and was designated VTT-C-99315. The control strain for it is yeast strain H2155 which carries the plasmid pYES2 in H452 background.

15

Example 22**Separation of yeast cells expressing HFBI-Flo1 fusion protein in ATPS**

The *Saccharomyces cerevisiae* strain VTT-C-99315 (vector pTNS23) and its control strain 20 H2155 (vector pYES2) were cultivated on synthetic complete medium lacking uracil (SC-URA) (Sherman, 1991) with 2% galactose as the carbon source to give an A_{600} of approximately 4. Approximately 6.3×10^8 cells in their culture medium were taken to ATPS using 7% (w/v) C12-18EO5 detergent (Agrimul NRE from Henkel) in a total volume of 5 ml. ATPS was carried out using standard protocol. After phase separation by gravity settling, 25 the top detergent phase was clearly turbid in the case of the strain VTT-C-99315 in contrast to the control strain whose detergent phase was clear (Figure 17). Samples were taken from the top phases and dilution series from 10^{-1} to 10^{-5} were prepared in 0.9% NaCl and plated on YPD plates. After incubation at 30°C the amount of yeast colonies were calculated showing at least 70 times more yeast colonies of the strain VTT-C-99318 on YPD plates compared to 30 the control strain. This clearly manifests that also in a system over-loaded with cells, separation to the detergent phase of cells expressing a hydrophobin on cell surface occurs.

Example 23**Partitioning of EGIcore-HFBI fusion protein in hydrophobin-containing and non-containing pure systems**

5 The effect of free HFBI and HFBII hydrophobins on the partitioning of EGIcore-HFBI was investigated by comparing how efficiently a sample of purified EGIcore-HFBI in 50 mM acetate buffer pH 5.0 was extracted to the detergent phase in the presence and absence of purified HFBI and HFBII. The extraction was followed by measuring the depletion of hydrolytic activity on a soluble substrate such as methylumbelliferyl 10 cellobioside in the aqueous phase before and after extraction. When 0.7 g/l of either purified hydrophobin was present in the separation of 0.02 g/l of EGIcore-HFBI with 2% C12-18EO5 at 30°C the extraction was affected in the following way: 93% of the protein was extracted when additional hydrophobin was not present, but with HFBII present 82% was extracted and with HFBI present 88% was extracted.

15

Example 24**Production of EGIcore-HFBI fusion proteins in *T. reesei* $\Delta hfb2$ strain for improved partitioning of the fusion protein in ATPS**

20 *Trichoderma reesei* strain QM9414 $\Delta hfb2$ (VTT-D-99726) was transformed essentially as described (Penttilä *et al.*, 1987) using 10 µg of the plasmid pMQ113 (described in Example 1) together with 3 µg of the selection plasmid pTOC202 containing the *amdS* gene (Hynes *et al.*, 1983); Tilburn *et al.*, 1983) of *Aspergillus nidulans* encoding for acetamidase. pMQ113 contains an expression cassette for production of EGIcore-HFBI fusion protein under the 25 control of *cbbh1* promoter and terminator sequences.

The Amd⁺ transformants obtained were streaked two times onto plates containing acetamide (Penttilä *et al.*, 1987). Thereafter spore suspensions were made from transformants grown on Potato Dextrose agar (Difco). The production of the EGIcore-HFBI fusion protein was 30 tested by slot blotting or Western analysis with EGI and HFBI specific antibodies from shake flask or microtiter plate cultivations carried out in minimal medium supplemented with Solka

flock cellulose. The spore suspensions of the clones producing fusion protein were purified to single spore cultures on selection plates containing acetamide. To determine the best producers, production of the fusion protein was analyzed again from these purified clones as described above.

5

For partitioning experiments of the EGIcore-HFBII fusion protein in ATPS using the polyoxyethylene detergent C12-18EO5 the best production strain obtained in this study and as control strains VTT-D-98691 (QM9414 strain producing EGIcore-HFBII) and VTT-D-74075 (QM9414) were cultivated in shake flasks on medium containing Solka flock cellulose 10 as described in Example 4.

Standard partitioning experiments as described in Example 5 are carried out with culture supernatants. After separation the volume ratio of the lighter and heavier phase is noted and the concentration factor for the fusion protein is calculated from it. Samples are also taken 15 from the lighter and heavier phase and analysed with SDS-PAGE, Western blotting and activity measurements as described in Example 5. Partition coefficients (K) and yields (Y) are calculated as described in Example 5.

Example 25

20 **Construction of vectors for expression of EGIcore-HFBII and EGIcore-SC3 fusion proteins under the *cbbI* promoter of *T. reesei***

For construction of an expression vector for production of EGIcore-HFBII fusion protein, *hfb2* (SEQ ID 20) coding region (from Ala-16 to the STOP codon) was amplified by PCR 25 using phfb2 (Nakari-Setälä et al. 1997) as a template and as a 5' primer **CGG AGG AGC TCG ACG ACT TCG AGC AGC CCG AGC TGC ACG CAG GCT GTC TGC CCT ACC GG** (SEQ ID 21) and as a 3' primer **TCA TTG GAT CCT TAG AAG GTG CCG ATG GC** (SEQ ID 22). The sequence is bold in the 5' primer encodes for amino acids 413-425 of EGI and the underlined GAGCTC is a SacI site. The underlined GGATCC in the 3' 30 primer is a BamHI site. The amplified fragment was digested with SacI and BamHI and ligated to pMQ113 cut with the same restriction enzymes. The resulting plasmid is pTNS32

(Figure 18) and it carries the coding sequence for EGICore-HFBII fusion protein under the control of *cbh1* regulatory sequences (SEQ ID 5 and SEQ ID 7).

For construction of an expression vector for production of EGICore-SC3 fusion protein, SC3 cDNA (SEQ ID 23) was amplified with PCR using cSC3/pUC20 plasmid as a template and as a 5' primer ACT ACA CGG **AGG AGC TCG** ACG ACT TCG AGC AGC CCG AGC TGC ACG **CAG** GGT GGC CAC CCG GGC (SEQ ID 24) and as a 3' primer TCG TAC **GGA TCC** TCA GAG GAT GTT GAT GGG (SEQ ID 25). The sequence is bold in the 5' primer encodes for amino acids 413-425 of EGICore and the underlined GAGCTC is a SacI site.

The underlined GGATCC in the 3' primer is a BamHI site. The amplified fragment was digested with SacI and BamHI and ligated to pMQ103 (described in Example 1) cut with the same restriction enzymes. The resulting plasmid is pTH4 (Figure 19) and it carries the coding sequence for EGICore-SC3 fusion protein under the control of *cbh1* regulatory sequences (SEQ ID 5 and SEQ ID 7).

The cSC3/pUC20 plasmid contains the 411 bp SC3 cDNA from the translational start site to the STOP codon in a pUC20 vector. The translational start site has been constructed to a NcoI site and a BamHI site has been added after the translational STOP codon.

20 Example 26

Construction of a vector for expression of a HFBI-dCBD fusion protein containing hydrophobin I and double cellulose binding domains (CBD) under the *cbh1* promoter of *T. reesei*

For construction of an expression cassette for production of HFBI -dCBD fusion protein under *cbh1* promoter, the protein coding region of *hfb1* was amplified with PCR using pEA10 (Nakari-Setälä et al. Eur. J. Biochem. (1996) 235:248-255) as a template. GGA ATT **CCG CCG ACT GCG CAT CAT GAA GTT CTT CGC CAT CGC C** (SEQ ID 26) was used as a 5' primer in the PCR and TGA ATT **CCA TAT GTT AGG TAC CAC** CGG GGC CCA TGC CCG TAG AAG TAG AAG CCC CGG GAG CAC CGA CGG CGG TCT GGC AC (SEQ ID 27) as a 3' primer. The sequence in bold in the 5' primer is 16 bp of *cbh1* promoter adjacent to translational start site of the corresponding gene

and the underlined CCGCGG is a KspI site. The underlined and bold sequences in the 3' primer are NdeI and Asp718 sites, respectively. The sequence in Italics in the 3' primer encodes for a Methionine-containing linker (PGASTSTGMGPGG). The resulting fragment of 370 bp was digested with KspI and NdeI and ligated to pAMH110
5 (Nevalainen, K.M.H., Penttilä, M.E., Harkki, A., Teeri, T.T. and Knowles, J. (1991) In Molecular Industrial Mycology. Eds. Leong, S.A. and Berka, R.. Marcel Dekker. New York) digested with same restriction enzymes. The resulting plasmid is pTNS29-2Asp.

For further cloning steps, an Asp718 site was removed from the pTNS29-2Asp
10 polylinker. The vector was digested with SacI and BamHI and the cleaved vector ends were blunted with T4 DNA polymerase and ligated together. The resulting vector pTNS29 is missing the SacI, Asp718 and SmaI sites present in the pTNS29-2Asp polylinker.

15 In the next step, a double cellose binding domain (dCBD) was amplified with PCR using pTNS11 as a template. pTNS11 carries the coding sequence for a fusion protein containing *T. reesei* CBHII CBD (41 N-terminal residues of CBHII) and CBHI CBD linked together via CBHI linker region (CBHI linker and CBD are the last 57 residues in CBHI). This DNA sequence originates from an *E. coli* expression vector B599 which is
20 essentially the same as the one described by Linder et al. (J. Biol. Chem. (1996) 271:21268-21272). TGA ATT CGG TAC CCA GGC TTG CTC AAG CGT C (SEQ ID 28) was used as a 5' primer in the PCR and TGA ATT CCA TAT GTC ACA GGC ACT GAG AGT AGT A (SEQ ID 29) as a 3' primer. The underlined sequences in the 5' and 3' primers are Asp718 and NdeI sites, respectively. The amplified fragment was digested
25 with Asp718 and NdeI and ligated to pTNS29 digested with Asp718 and NdeI resulting in pTNS30.

pTNS30 (Figure 20) expression vector thus carries the coding region for a fusion protein consisting of HFBI and double CBD linked in frame via the Methionine linker peptide
30 (PGASTSTGMGPGG). Expression of the fusion protein is regulated by the *cbbI* transcriptional control sequences. The expression cassette may be released from the plasmid with EcoRI and SphI

Example 27**Construction of vectors for expression of HFBI-single chain antibody fusion proteins under the *cbh1* promoter of *T. reesei***

5 An expression vector was constructed for production of a fusion protein consisting of *T. reesei* HFBI protein in the N-terminus and in the C-terminus a single chain antibody recognizing a small molecular weight derivative of diarylalkyltriazole (ENA5ScFv). Production of the fusion protein is under the *cbh1* regulatory sequences. For construction of HFBI-ENA5ScFv fusion protein, pENA5ScFv was digested with NcoI and XbaI. The 10 fragment containing the *ena5scfv* gene and the histidine tail (6 x His) was blunt-end cloned to pTNS29 resulting in pTH1 (Figure 21). pENA5ScFv vector carries the coding region for ENA5 single chain antibody consisting of the variable domains of the heavy and light chains connected via a glycine serine linker and a 6 x histidine tag at the C-terminal end. Transcription and secretion of the single chain antibody are under control of the *tac* promoter 15 and *pelB* signal sequence, respectively (Takkinen *et al.*, 1991). pTNS29 vector carries the *hfb1* coding region of *T. reesei* followed by a linker sequence (ProGlyAlaSerThrSerThrGlyMetGlyProGlyGly) under the control of *cbh1* promoter and terminator sequences.

20 For construction of HFBI-ENA5ScFv fusion protein with a thrombin cleavage site in the linker peptide, *ena5scfv* coding region (from Ala-23 to the STOP codon) and a peptide linker containing the thrombin cleavage site (Gly Thr Leu Val Pro Arg Gly Pro Ala Glu Val Asn Leu Val) preceding it was amplified with PCR using pENA5ScFv as a template and as a 5' primer GAA TTC **GGT ACC** CTC GTC CCT CGC GGT CCC **GCC GAA GTG AAC**

25 **CTG GTG** (SEQ ID 30) and as a 3' primer TGA ATT **CCA TAT GCT AAC CCC GTT** TCA TCT CCA **G** (SEQ ID 31). The sequence in bold in the 5' primer encodes the first 6 N-terminal residues of ENA5SCFV. The sequence in italics is a thrombin cleavage site and underlined GGT ACC is an Asp718 site. The sequence in bold in the 3' primer encodes the 6 C-terminal residues of ENA5ScFv and the underlined CA TATG is a NdeI site. The 790 bp 30 PCR fragment was purified from agarose gel and ligated to pTNS29 resulting in pTH2 (Figure 22).

Example 28**Construction of a vector for production of class I hydrophobin SC3 of *Schizophyllum commune* in *Trichoderma reesei* for ATPS**

5 A *T. reesei* strain producing class I hydrophobin SC3 of *S. commune* was constructed. For that purpose an expression vector carrying the SC3 cDNA under the control of *hfb2* promoter and *hfb1* terminator of *T. reesei* was constructed.

The *hfb1* terminator (SEQ ID 32) was amplified with PCR using as a template pEA10
10 (Nakari-Setälä et al. 1996) and as a 5' primer GAC CTC GAT GCC CGC CCG GGG TCA
AG (SEQ ID 33) and as a 3' primer GTC GAC ATT TCA TTT TAC CCC CCT CG
(SEQ ID 34). The underlined sequences in the 5' and 3' primers are SacI and SalI sites,
respectively. The PCR fragment was cut with SacI and SalI so that the SacI site was
blunted with Klenow. The fragment was cloned into cSC3/pUC20 (described in Example
15 25) vector digested with SalI and BamHI where the BamHI was blunted with Klenow. In
the next step, the *hfb2* promoter (SEQ ID 35) was amplified with PCR using as a template
pTNS8 (Nakari-Setälä et al. 1997) and using as a 5' primer AAG CTT GCA TGC CTG
CAT CC (SEQ ID 36) and as a 3' primer CCA TGG TGA AAG GTG GTG ATG GTT
GG (SEQ ID 37). The underlined sequences in the 5' and 3' primers are HindIII and
20 NcoI sites, respectively. The PCR fragment was digested with HindIII and NcoI and
cloned in front of the SC3 cDNA in the plasmid obtained in the previous step and cut
with the same restriction enzymes. The resulting plasmid is pKS2 (Figure 23).

Example 29

25 **Construction of *T. reesei* strains producing EGICore-HFBII, EGICore-SC3, HFBI-dCBD and HFBI-single chain antibody fusion proteins, and SC3 hydrophobin**

Trichoderma reesei strains VTT-D-74075 (QM9414), VTT-D-86271 (Rut-C30) and VTT-
D-99676 (Rut-C30 Δ *hfb2*) were co-transformed essentially as described (Penttilä et al.,
30 1987) using 3-13 μ g of the plasmids pTNS32, pTH1, pTH2, pTH4, pTNS30 and pKS2 and
as the selection plasmids 1-3 μ g pToC202 or pARO21. pToC202 carrying the *amdS* gene
(Hynes et al., 1983; Tilburn et al., 1983) of *A. nidulans* and pARO21 carrying the *E. coli* *hph*

gene have been described in Example 3. The Amd⁺ and Hyg⁺ transformants obtained were streaked three times onto plates containing acetamide and hygromycin, respectively (Penttila *et al.*, 1987). Thereafter spore suspensions were made from transformants grown on Potato Dextrose agar (Difco).

5

The production of the fusion proteins EGICore-HFBII, EGICore-SC3, HFBI-dCBD and HFBI-ENA5ScFv and the SC3 hydrophobin was tested by slot blotting or Western analysis with EGICore, SC3, CBD and HFBI specific antibodies from shake flask or microtiter plate cultivations carried out in minimal medium supplemented with either lactose or Solka flock 10 cellulose. The spore suspensions of the fusion protein producing clones were purified to single spore cultures on selection plates (containing either acetamide or hygromycin). To determine the best producers, production of the fusion proteins was analyzed again from these purified clones as described above.

15 *T. reesei* strains selected for further cultivations are X46A (pTNS32, host QM9414), VTT-D-00793 (pTH4, host Rut-C30 Δ hfb2), VTT-D-99727 (pTNS30, host Rut-C30 Δ hfb2), VTT-D-00791 (pTH1, host Rut-C30) and VTT-D-00792 (pKS2, host Rut-C30 Δ hfb2). These strains were cultivated as described in Example 4 and the culture supernatants were subjected to ATPS.

20

Example 30

Recovery of the protein product from the enriched detergent phase after ATPS by isobutanol or other solvents

25 After phase separation has occurred and the hydrophobin or the hydrophobin fusion protein is enriched in the detergent phase (the enriched phase), the protein can be recovered to an aqueous buffer by addition of isobutanol or other solvent. For example a series, of identical extractions of 0.05 g/l HFBI in 50 mM acetate buffer was made with 2% Berol 532. To separate tubes 10% final concentration of either isobutanol, n-amyl 30 alcohol, octanol, or octane was added, and the fraction of hydrophobin recovered to the aqueous phase was analyzed. It was found that 100% was recovered with isobutanol,

89% with n-amyl alcohol, 81 % with octanol and 70 % with octane. Fractions were analyzed by HPLC as described in Example 38.

5 Example 31

Separation of EGICore-HFBII fusion protein in ATPS.

T.reesei strain X46A was grown in shake flasks on 3% lactose medium as described in Example 4. C12-18EO5 detergent was added to a final concentration of 5% to the culture supernatant. After mixing the system was allowed to settle and the enriched 10 detergent phase was subjected to further extraction with an equal volume of isobutanol. After buffer exchange on Biogel P-6 (Bio-Rad, USA) gel filtration media, the extracted protein was analysed by ion exchange chromatography using a Mono Q (Amersham Pharmacia, Sweden) column equilibrated with 15 mM acetate and eluted using a linear gradient of NaCl. Separation of the EGICore-HFBII fusion protein to the detergent phase 15 was verified by analyzing the eluted peak fraction from the Mono Q chromatography run by its activity on 4-methylumbelliferyl cellobioside as well as its re-extraction by ATPS.

Example 32

Separation of EGICore-SC3 fusion protein in ATPS

20 Culture filtrate of *T.reesei* strain VTT-D-00793 producing EGICore-SC3 fusion protein was subjected to ATPS by adding 5% final concentration of C12-18EO5. After the settling, the phases were separated and the fusion protein enriched detergent phase was further treated with an equal volume of isobutanol which removes the detergent to the 25 isobutanol and leaves the protein in the aqueous phase. The resulting fusion protein enriched aqueous phase was then desalted on Biogel P-6 (Biorad, USA). Separation of fusion protein to the detergent phase was verified by analyzing the enzymatic activity of the EGICore fusion partner on 4-methylumbelliferyl cellobioside in that phase.

Example 33**Separation of HFBI-dCBD fusion protein in ATPS**

T. reesei strain VTT-D-99727 producing HFBI-dCBD fusion protein was grown on

5 lactose-containing medium as described in Example 4. Berol 532 was added to a final concentration of 2 % to 500 ml of culture supernatant. The mixture was allowed to settle and the phases separated in a separation funnel. The enriched top phase (10 ml) was extracted with an equal volume of isobutanol and 50 mM acetate buffer pH5. The fusion protein was selectively enriched to the buffer in the separation as shown by SDS gel

10 electrophoresis (Figure 24).

Example 34**Recovery of the HFBI-dCBD fusion partners after chemical cleavage**

15 HFBI-dCBD protein produced by the strain VTT-D-99727 has a methionine (PGASTSTGMGPGG) designed in the linker region between the HFBI and the dCBD, which would enable the recovery of the native HFBI and dCBD after chemical cleavage with CNBr.

20 The HFBI-dCBD fusion protein was purified as described in Example 33. The resulting water phase (~108 ml) still contained a small amount of CBHI and free hydrophobin in addition to the HFBI-dCBD fusion (Figure 24). Further purification of the sample was performed by chromatography. The sample was desalted on a Biogel P-6 column equilibrated with 50mM sodium acetate buffer pH 5.5, diluted 1 + 3 with water and applied on a CM-Sepharose FF

25 column equilibrated with 10mM sodium acetate buffer pH 5.5. The CBHI protein was found in the flow through and the purified HFBI-dCBD protein was eluted with 0.2M NaCl.

A sample of purified HFBI-dCBD protein was evaporated in speed-vac almost to dryness. CNBr cleavage was performed by adding a solution of CNBr in 0.1M HCl (5mg/ml) to the

30 evaporated sample in 5 times weight excess. The reaction was allowed to continue for 24h at room temperature (in dark). A 10 times volume of water was added and the sample was

evaporated in speed-vac almost to dryness. The evaporated sample was diluted in 50mM Tris-HCl pH 7 and the cleavage was confirmed by HPLC analysis as described in Example 37.

5 The treatment was further optimised by using different concentrations of HCl and incubation times. The final CNBr treated sample was subjected to ATPS as described in Example 33. HFBI was found in the top-phase and the dCBD in the bottom phase, thus leading to a separation of both fusion partners.

10 **Example 35**

Separation of HFBI-single chain antibody fusion protein in ATPS

Strain VTT-D-00791 was cultivated for 7 days on medium containing 10 g/l potassium phtalate, 15 g/l KH_2PO_4 , 5 g/L $(\text{NH}_4)_2\text{SO}_4$ and 3% lactose and 0.2% peptone. 30 ml of 15 culture medium was subjected to ATPS using 4% C12-18-EO5 detergent as described in Example 5. After removal of the bottom phase, the detergent phase was extracted by isobutanol. Proteins from the water phase after detergent extraction and the bottom phase of the isobutanol extracted detergent phase were precipitated with trichloroacetic acid (final concentration 10%), resuspended in SDS-PAGE sample buffer (taking into account the 20 concentration factor of the isobutanol extracted detergent phase) and analysed by Western blotting using HFBI specific antibodies. The fusion protein runs as a dimer (approximately 70 kDa) in SDS-PAGE under the conditions used as seen in Figure 25. The water phase sample still contained a small amount of fusion protein. Nevertheless, separation of the fusion protein can be obtained by ATPS.

25

Example 36

Separation of SC3 hydrophobin in ATPS

SC3 hydrophobin producing strain VTT-D-00792 was cultivated in shake flasks on lactose-30 containing medium as described in Example 4. Soluble secreted proteins produced by the fungus were precipitated with trichloroacetic acid. Precipitated proteins were solubilized in trifluoroacetic acid to dissociate the SC3 aggregates whereafter the acid was evaporated with

a stream of air. The treated proteins were solubilized in 2 ml water containing 2.5 % of the detergent C12-18EO5. Phase separation was carried out as described in Example 5. Samples were taken from the lighter and heavier phase and analysed by Western blotting using SC3 specific antibodies. On the basis of this analysis, SC3 hydrophobin partitions to the detergent 5 phase (Figure 26).

Example 37**Separation of nisin in ATPS**

10 1 mg of pure nisin (Sigma) (equals to 1000 IU) in 50 mM sodium acetate buffer pH 5 was subjected to ATPS using 2% of the detergent C12-18EO5 at 30°C, and the phases were allowed to settle. After removal of the bottom phase, the detergent phase was extracted by isobutanol which removes the detergent to the isobutanol and leaves nisin in the aqueous phase. Separation of nisin to the enriched aqueous phase was assayed testing nisin 15 bioactivity as described by Qiao et al. 1996. Comparison of the halos on the assay plate produced by the enriched phase and the nisin controls indicated that nisin had separated to the detergent phase with a concentration factor of approximately 5.

20 Example 38**Preparative purification of HFBI and HFBII in ATPS**

For preparative purposes, HFBI and HFBII were extracted from 0.5 l of culture supernatants from cultivations carried out on media containing glucose or cellulose as 25 described in Example 4. 2% (w/w) detergent was added to the culture supernatant which was mixed and then allowed to settle in a separation funnel at 20°C if C11EO2 (Berol 532) was used and 30°C if C12-18EO5 (Henkel) was used. The detergent phase (enriched phase) was collected and mixed with an equal volume of isobutanol. When C11EO2 was used an equal volume of 50 mM acetate buffer was also added. The 30 remaining culture supernatant is the depleted phase. To follow the purification, analytical HPLC was run on samples from each step (Figure 27 and 28). On the basis of HPLC analysis, both HFBI and HFBII partitioned well to both of the detergents. When

C11EO2 was used, K values of >1000 and >78 were obtained for HFBI and HFBII, respectively.

Water phase after isobutanol extraction was collected and further purified on a Vydac 5 1x20 cm semipreparative C4 column (Vydac, USA) equilibrated with 0.1% trifluoro acetic acid in water and eluting with a linear gradient of 0.1% trifluoro acetic acid in acetonitrile. The proteins were then lyophilized. In analytical runs a 4.6 mmx20 cm Vydac C4 column was used.

10 **Example 39**

Screening for separation conditions using purified HFBI and HFBII

HFBI and HFBII which were purified from culture supernatants in ATPS, further purified by preparative HPLC and lyophilized as described in Example 38 were dissolved 15 in water to a concentration of 0.5 mg/ml. The stock solutions were then diluted with the buffer appropriate for the experiment. 50 mM acetate buffer pH5, 50 mM glycine pH 3, 50 mM HEPES pH 7 was used for pH screening and NaCl or $(\text{NH}_4)_2\text{SO}_4$ in acetate buffer was used for ionic strength experiments. The surfactant was weighed with the appropriate amount of hydrophobin solution and incubated in 0, 20, 30, 40°C and the 20 amount of hydrophobin in the depleted phase determined. Partitioning coefficients were calculated from the change in concentration and the volume ratios and are presented in the tables below.

Table presenting K-values for the separation of hydrophobins with different surfactants and temperature.

	Temperature	Henkel	Berol 532	Berol 266	Triton x114
HFBI	0°C	0,1	368	NP	NP
	20°C	0,4	1961	NP	NP
	30°C	85	2970	NP	0,9
	40°C	148	682	28	69
HFBII	0°C	NP	76	NP	NP
	20°C	1,0	139	NP	NP
	30°C	67	194	NP	4,0
	40°C	44	102	19	44

5 NP = no phase separation

Table presenting the effect of different salt concentrations at 40°C on K-values

10

		Henkel	Berol 532	Berol 266	Triton x114
HFBI	50 mM buffer	244	578	13	39
	+ 1 M NaCl	239	33	198	241
	+ 1 M (NH ₄) ₂ SO ₄	0,9	3,2	176	612
HFBII	50 mM buffer	36	80	16	58
	+ 1 M NaCl	14	87	61	38
	+ 1 M (NH ₄) ₂ SO ₄	3,1	351	95	35

15 Table presenting the K-values for the partitioning of hydrophobins in Berol 532 at different conditions.

	HFBI 0°C	HFBI 20°C	HFBII 0°C	HFBII 20°C
50 mM acetate pH5	298	614	76	127
+1 M NaCl	614	3781	131	199
+1M (NH ₄) ₂ SO ₄	931	44	203	139
pH3	614	1881	73	160
pH7	361	614	54	126

Example 40**Purification of a new putative *T. reesei* hydrophobin on the basis of its separation in ATPS, and cloning of the corresponding gene**

5 *T. reesei* strain VTT-D-99726 (QM9414 Δ hyb2) was cultivated on lactose-based medium in 15 fermentor as described in Example 4. After cultivation, 1 l of the culture filtrate was subjected to ATPS with 5% polyoxyethylene detergent C12-18EO5. After phase separation at 30°C, detergent phase was separated from the depleted aqueous phase and analysed by SDS-PAGE. The analysed sample contained a protein which
10 was about 7.5 kDa. In addition, some larger proteins were present. These were removed by hydrophobic interaction chromatography on a Phenyl-Sepharose FF column equilibrated with 50 mM sodium acetate - 1 M $(\text{NH}_4)_2\text{SO}_4$ buffer. The proteins were eluted with descending $(\text{NH}_4)_2\text{SO}_4$ salt gradient. Fractions containing the ca. 7.5 kDa protein were pooled and concentrated, and analysed by mass
15 spectrometry. This revealed that the purified protein was degraded to three peptides (2486, 2586 and 2709 Da), which were held together by disulphide linkages. The N-terminal amino acid sequence from the 2486 Da peptide was ANAFCPEGLLYTNPLCCDLL, which on the basis of position of cysteines and on sequence comparison to known hydrophobins is typical to a hydrophobin.

20

Degenerated primers were designed on the basis of this amino acid sequence as well as on the basis of the sequence obtained from the 2586 Da peptide. These primers were used in RT-PCR (RobusT RT-PCR Kit, Finnzymes) with RNA isolated from the same cultivation from where the protein was purified. The 140 bp fragment obtained
25 from the RT-PCR reaction was sequenced. The obtained sequence contained a part that was coding for the 2486 Da peptide used to design the PCR primer confirming that the PCR product corresponds to the purified protein.

30

Example 41**Purification of EGICore-HFBI in ATPS in pilot scale**

The strain VTT-D-99702 producing EGICore-HFBI fusion under the *cbh1* promoter was
5 cultivated in pilot scale fermentor in 1200 L on minimal medium containing 4% lactose,
0.4 % peptone and 0.1% Yeast Extract for 4 days. Cultivation temperatures were 28°C
or alternatively the temperature was changed during the cultivation from 27°C to 22°C in
a step-wise manner. Production level of the fusion protein was a few grams per liter
After the end of the cultivation, the mycelium was separated by means of a rotating
10 vacuum drum filter using Celite 535 diatomaceous earth as filter aid.

In separation 1, 1100 L of the supernatant was transferred into the meanwhile cleaned
bioreactor, adjusted to the separation temperature of 24,7 °C and mixed with salt and
detergent to give 0,15 M ammonium dihydrogen phosphate and 4,1 % of detergent C12-
15 18EO5. The phases were left to separate by gravity settling and the heavier phase
removed through the bottom valve. A parallel experiment in 10 ml volume was carried
out to investigate the effect of scale up on the separation of the fusion protein. The
partition coefficient and the concentration factor were equal for the 10 ml and 1200 L
separation within the measurement error. The separated detergent phase was re-
20 extracted using the detergent phase from the first extraction by replacing half of the
volume of the bottom phase by tap water. The salt concentration was adjusted to 0,25 M
ammonium dihydrogen phosphate at 30°C. K and Y values of the separations are
presented in the below Table.
25 Alternatively in separation 2, 10 ml of drum filtrated culture medium samples were
subjected to ATPS at 25°C using 4,1% C12-18EO5 detergent and 1,15 M (NH₄)H₂PO₄.
K and Y values after one separation step are presented in the Table below.

Table presenting extraction experiments of culture supernatants from different pilot scale cultivations

Separation	Cultivation temperature	Concentration factor	K	Y [%]
Separation 1	27°C → 22°C	3.4	3.8	59
Re-extraction			8	70
Separation 2	29°C	2.8	8.3	81

5

Example 42

Separation of EGI, EGIcore-HFBI fusion protein and HFBI hydrophobin in robust micelle/polymer systems

10 Separations were performed with purified samples. HFBI was purified by two-phase separation and HPLC as described in Example 38. EGIcore-HFBI was purified by two-phase extraction as described in Example 5 followed by desalting on a Biogel P-6 column equilibrated with 20mM sodium acetate buffer pH 6 containing 150mM NaCl. The purified proteins were subjected to ATPS using different micelle/polymer systems.

15

The table below presents partitioning coefficients of pure EGI, HFBI and EGIcore-HFBI at constant tie-line length, in the different systems, Triton X-114/water system (4.1 % wt.) at 31.5° C, Triton X-100/Reppal/water system (8.1 % wt. / 8.2 % wt.) and Triton X-114/Reppal/water system (5.0 % wt. / 4.0 % wt.) at 21° C. The standard deviation is 20 shown within the brackets. The systems were buffered with 25 mM sodium acetate, pH 4.0. K > 1 is equivalent to a preferred protein partitioning to the micelle rich phase.

	EGI	HFBI	EGIcore-HFBI	
	K _{EGI}	K _{HFBI}	K _{EGIHFBI}	Yield (%) top phase
Triton X-114	0.6 (0.1)	21.5 (1.5)	8.4 (1.0)	85
Triton X-100/Reppal	0.9 (0.1)	-	1.7 (0.1)	56
Triton X-114/Reppal	0.7 (0.1)	11.0 (1.1)	15.4 (2.9)	91

References

Albertsson, P.A. (1986). Partition of Cell Particles and Macromolecules, John Wiley & Sons, New York.

Arntz, C. and Tudzynski, P. (1997). Identification of genes induced in alkaloid-producing cultures of *Claviceps* sp. Curr. Genet. 31:357-360.

Bender, W. and Koglin, B. (1986). Mechanische Trennung von Bioprodukten. Chem.-Ing.-Tech., 58:565-577.

Berggren K., Veide A., Nygren P.-A. and Tjerneld F. (1999). Genetic engineering of protein-peptide fusions for control in thermoseparating aqueous two-phase systems. Biotechnol. Bioeng. 62:135-144.

Bhikhabhai, R., Johansson, G. and Petterson, G. (1984). Isolation of cellulolytic enzymes from *Trichoderma reesei* QM 9414. J. Appl. Biochem. 6:336-345.

Bordier C. (1981). Phase Separation of Integral Membrane Proteins in Triton X-114 Solution. J. Biol. Chem. 25:1604-1607.

Carpenter, C.E., Mueller, R.J., Kazmierczak, P., Zhang, L., Villalon, D.K. and van Alfen, N.K. (1992). Mol. Plant-Microbe Interact. 4:55-61.

Gietz, D., St. Jean, A., Woods, R.A. and Schiestl, R.H. (1992). Improved method for high efficiency transformation of intact yeast cells. Nucl. Acid. Res. 20:1425.

Hassinen C., Köhler K., Veide A. (1994). Polyethylene glycol - potassium phosphate aqueous two-phase systems: A study using model proteins. Biotechnol. Bioeng. 44:626-635

Heusch, R. and Kopp, F. (1988). Structures in aqueous solutions of nonionic tensides. Progress in Colloid & Polymer Science, 77:77-85.

Hustedt, H., Kroner, K. and Kula, M.R. (1985). Applications of Phase Partitioning in Biotechnology. In: Walter, H., Brooks, D.E. and Fisher, D. (eds.), Partitioning in Aqueous Two-Phase Systems: Theory, Methods, Uses and Applications to Biotechnology, pp. 529-587.

Hynes, M.J., Corrick, C.M. and King, J.A. (1983). Isolation of genomic clones containing the *amdS* gene of *Aspergillus nidulans* and their use in the analysis of structural and regulatory mutations. Mol. Cell Biol. 3:1430-1439.

Johansson, H.-O., Karlström, G., Tjerneld, F. and Haynes, A. C (1998). Journal of Chromatography B, 711:3-17.

Kershaw, M.J. and Talbot, N.J. (1998). Hydrophobins and repellents: proteins with fundamental roles in fungal morphogenesis. Fungal Gen. Biol. 23:18-33.

Kula M-R. (1979). Extraction and Purification of Enzymes Using Aqueous Two-Phase Systems. In: Wingard L; Goldstein, L (eds.), *Applied Biochemistry and Bioengineering*. New York, Academic Press, pp. 71-95.

Kula, M-R., Kroner, K.H., Hustedt, H. and SchüKe, H. (1981). Technical aspects of extractive enzyme purification. *Ann. N.Y. Acad. Sci.*, 369:341-354.

Kula, M-R., Kroner, K.H. and Hustedt, H. (1982). Purification of enzymes by liquid-liquid extraction. In: Fiechter, A. (ed.), *Advances in Biochemical Engineering*, Springer Verlag, Berlin, pp. 74-118.

Kula, M-R. (1985). Liquid-Liquid Extraction of Biopolymers. In: Humphrey A; Cooney CL (eds.), *Comprehensive Biotechnology*, Vol. 2. Pergamon Press, New York, pp. 451-471.

Kula, M-R. (1990). *Bioseparation*, 1:181-189.

Köhler, K., Ljungquist, C., Kondo, A., Veide, A. and Nilsson B. (1991), Engineering proteins to enhance their partition coefficient in aqueous two-phase systems. *Bio/Technology* 9:642-646.

Linder, M., Salovuori, I., Ruohonen, L. and Teeri, T.T. (1996). Characterization of a double cellulose-binding domain. *J. Biol. Chem.* 271:21268-21272.

Lora, J.M., de la Cruz, J., Benitez, T., Llobell, A. and Pintor-Toro, J.A. (1994). *Mol. Gen Genet.* 242:461-466.

Lora, J.M., Pintor-Toro, J.A., Benitez, T. and Romero, L.C. (1995). *Mol. Microbiol.* 18:377-382.

Mach *et al.*, (1994) *Curr. Genet* 6:567-570.

Minuth, T., Thömmes, J. and Kula, M-R. (1995). Extraction of cholesterol oxidase from *Nocardia rhodochrous* using a nonionic surfactant-based aqueous two-phase system. *J. Biotechnol.* 38:151-164.

Minuth, T., Thömmes, J. and Kula, M-R. (1996). A closed concept for purification of the membrane-bound Cholesterol-Oxidase from *Nocardia rhodochrous* by surfactant-based cloud-point extraction, organic solvent extraction and anion-exchange chromatography *Biotechnol. Appl. Biochem.* 23:107-116.

Nakari, T., Onnela, M.-L., Ilmén, M., Nevalainen, K.M.H. and Penttilä, M. (1994) Fungal promoters active in the presence of glucose. International Patent Appl. WO 94/04673

Nakari-Setälä *et al.* (1996). *Eur. J. Biochem.* 235:248-255.

Nevalainen, K.M.H., Penttilä, M.E., Harkki, A., Teeri, T.T. and Knowles, J. (1991) The Molecular Biology of *Trichoderma* and Its Application to the Expression of Both

Homologous and Heterologous Genes. In Molecular Industrial Mycology. Leong, S.A. and Berka, eds., R.. Marcel Dekker. New York, p.129-148.

Pack, P., Kujau, M., Schroeckh, V., Knupfer, U., Wenderoth, R., Riesenber, D. and Pluckthun, A. (1993). Improved bivalent miniantibodies, with identical avidity as whole antibodies, produced by high cell density fermentation of *Escherichia coli*. Biotechnology 11:1271-1277.

Penttilä, M., Nevalainen, H., Rättö, M., Salminen, E. and Knowles, J. (1987). A versatile transformation system for the cellulolytic filamentous fungus *Trichoderma reesei*. Gene 61:155-164.

Pere, J., Siika-aho, M., Buchert, J. and Viikari. L. (1995). Effect of purified *Trichoderma reesei* cellulases on the fiber properties of kraft pulp. Tappi Journal 78:71-78.

Qiao, M., Ye, S., Koponen, O., Ra, R., Usabiaga, M., Immonen, T., Saris, P.E.J. (1996) Regulation of the nisin operons in *Lactococcus lactis* N8. J. Appl. Biochem. 80:626-634.

Russo, P.S., Blum, F.D., Ispen, J.D., Abul-Hajj, Y.J. and Miller, W.G. (1992). Can. J. Bot. 60: 1414-1422.

Schreuder, M.P. *et al.* (1996). Trends Biotechnol. 14:115-120.

Sherman, F., Fink, G.R. and Hicks, J.B. (1983). Methods in Yeast Genetics. A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.

Suominen, P., Mäntylä, A., Saarelainen, R., Paloheimo, M., Fagerström, R., Parkkinen, E. and Nevalainen, H. (1992). Genetic engineering of *Trichoderma reesei* to produce suitable enzyme combinations for applications in the pulp and paper industry. In: Kuwahara. M. and Shimada, M. (eds.) Biotechnology in Pulp and Paper Industry p.439-445. (Proc. 5th Int. Conf. Biotechn. Pulp Pap. Ind., Kyoto, Japan, 1992)

Ståhl, S. and Uhlén, M. (1997). Trends Biotechnol. 15:185-192.

Takkinen, K., Laukkonen, M.-L., Sizmann, D., Alftan, K., Immonen, T., Vanne, L., Kaartinen, M., Knowles, J.K.C. and Teeri, T.T. (1991). An active single-chain antibody containing a cellulase linker domain is secreted by *Escherichia coli*. Protein Eng. 4:837-841.

Temple, B., Horgen, P.A., Bernier, L. and Hintz, W.E. (1997). Cerato-ulmin, a hydrophobin secreted by the causal agents of Dutch Elm Disease, is a parasitic fitness factor. Fungal Gen Biol. 22:39-51.

Terstappen, G.C., Geerts, A.J., Kula, M.-R., 1992 "The use of detergent based aqueous two-phase systems for the isolation of extracellular proteins: Purification of a lipase from *Pseudomonas cepacia*", Biotechnol. Appl. Biochem. 16, 228-235

Terstappen, G. C., Ramelmeier, R. A. and Kula M.-R., 1993, Protein partitioning in detergent-based aqueous two-phase systems, J. Biotechnol. 28: 263-275

Thomas, B.J. and Rothstein, R. (1989). Elevated recombination rates in transcriptionally active DNA. *Cell* 56: 619-630.

van Tilbeurgh H. and Caeyssens M. (1985). Detection and differentiation of cellulase components using low molecular mass fluorogenic substrates. *FEBS letters* 187:283-288.

van Tilbeurgh H., Caeyssens M. and de Bruyne C.K. (1982). The use of 4-methylumbelliferyl and other chromophoric glycosides in the study of cellulolytic enzymes. *FEBS letters* 194:152-156.

Tilburn, J., Scazzocchio, C., Taylor, G.G., Zabicky-Zissman, J.H., Lockington, R.A. and Davies, R.W. (1983). Transformation by integration in *Aspergillus nidulans*. *Gene* 26:205-221.

Tjerneld, F., Bemer, S., Cajarville, A. and Johansson, G. (1986). New aqueous two-phase system based on hydroxypropyl starch useful in enzyme purification. *Enz. Microb. Technol.* 8:417-423.

Veide, A., Lindbäck, T. and Enfors, S. (1984). Continuous extraction of β -D-galactosidase from *Escherichia coli* in an aqueous two-phase system: effects of biomass concentration on partitioning and mass transfer. *Enz. Microb. Technol.* 6:325-330.

Walter, H., Brooks, D.E. and Fisher, D. (1985). Partitioning in Aqueous Two-Phase Systems, Academic Press, Inc., Orlando.

Watari, J., Nomura, M., Sahara, H. and Koshino, S. (1994). Construction of flocculent brewer's yeast by chromosomal integration of the yeast flocculation gene *FLO1*. *J. Inst. Brew.* 100:73-77.

Wessels, J.G.H. (1994). Developmental regulation of fungal cell wall formation. *Annu. Rev. Phytopathol.* 32:413-437.

Wösten, H.A.B., Schuren, F.H.J. and Wessels, J.G.H. (1994a). The fungal hydrophobin Sc3p self-assembles at the surface of aerial hyphae as a protein membrane constituting the hydrophobic rodlet layer. *Eur. J. Cell Biol.* 63:122-129

Wösten, H.A.B., Schuren, F.H.J. and Wessels, J.G.H. (1994b). Interfacial self-assembly of a hydrophobin into an amphipathic protein membrane mediates fungal attachment to hydrophobic surfaces. *EMBO J.* 13:5848-5854.

Wösten, H.A.B., Bohlmann, R., Eckerskorn, C., Lottspeich, F., Böker, M. and Kahmann R. (1996) *EMBO J.* 15:4274-4281.

Wösten, H.A.B. and Wessels, J.G.H. (1997). Hydrophobins, from molecular structure to multiple functions in fungal development. *Mycoscience* 38:363-374.

Claims

1. A process for partitioning of proteins or cells in aqueous two-phase systems (ATPS), comprising the steps of
 - 5 a) in order to obtain a fusion protein or cell, combining a protein or a cell of interest to a targeting protein selected from the group consisting of amphipathic and hydrophobic proteins having the ability to partition in ATPS and to carry said protein or cell of interest into one of the phases, and
 - 10 b) subjecting said fusion protein or cell carrying the targeting protein to an ATPS separation.
2. The process according to claim 1, wherein the targeting protein is a hydrophobin or hydrophobin-like protein or a part thereof.
- 15 3. The process according to claim 2, wherein the hydrophobin is a *Trichoderma* hydrophobin or a part thereof.
4. The process according to claim 3, wherein the *Trichoderma* hydrophobin is HFB1, HFB2 or SRH1, or a part thereof.
- 20 5. The process according to claim 1, wherein the amphipathic or hydrophobic proteins or parts thereof form aggregates.
6. The process according to any one of claims 1 to 5 for partitioning cells in ATPS, 25 wherein in step a) of claim 1 the combination of the cells of interest to the targeting protein comprise bringing said targeting protein onto the surface of said cells.
7. The process according to claim 6, wherein the cells are yeast cells.
- 30 8. The process according to claim 6 wherein the cells are spores.
9. The process according to any one of claims 6 to 8, wherein the targeting protein is fused to a protein which brings the targeting protein onto the surface of the cell.

10. A fusion protein, comprising a hydrophobin or hydrophobin-like protein as defined in any one of claims 2 to 5 fused to a protein of interest.
11. The fusion protein according to claim 10, wherein the protein of interest is a cell-bound protein or a part thereof.
12. The fusion protein according to claim 10, wherein the protein of interest is an extracellular protein or a part thereof.
- 10 13. The fusion protein according to claim 12, wherein the extracellular protein is an extracellular protein of *Trichoderma*, selected from the group consisting of cellulases, hemicellulases and proteases.
14. The fusion protein according to claim 10, wherein the protein of interest is an antibody protein or a part thereof.
- 15 15. The process according to claim 1, wherein the targeting protein is fused to the protein of interest according to any one of the claims 10 to 14.
- 20 16. A recombinant organism producing a fusion protein according to any one of claims 10 to 14.
17. The recombinant organism according to claim 16, wherein the organism has been genetically modified to be capable of producing a fusion protein according to any one of claims 10 to 14.
- 25 18. A recombinant DNA molecule, comprising a DNA molecule encoding a fusion protein according to any one of claims 10 to 14.
- 30 19. A process for producing a fusion protein according to any one of the claims 10 to 14 with recombinant organisms, comprising the steps of
 - a) transforming the organism with DNA molecules enabling expression of such proteins, and

b) recovering such protein from the culture of the recombinant organism.

20. The process according to any one of claims 1 to 9 and 15, wherein the aqueous two-phase system is selected from the group consisting of PEG/salt, PEG/Dextran and

5 PEG/starch systems or derivatives thereof, detergent-based aqueous two-phase systems and thermoseparating polymer systems.

21. The process according to claim 20, wherein the detergent-based ATPS comprises a detergent which is selected from the group consisting of nonionic and zwitterionic

10 detergents.

22. The process according to claim 20, wherein the thermoseparating polymer system comprises a polymer which is selected from the group consisting of polyethylene-
15 polypropylene copolymers.

23. The process according to any one of claims 1-9 and 15, wherein the protein or cell of interest is separated from a suspension containing cells or cell extracts.

24. A process for separating hydrophobins or hydrophobin-like proteins or parts thereof
20 in aqueous two-phase systems, comprising the steps of
a) mixing solutions containing said hydrophobin, hydrophobin-like protein or parts thereof with the phase forming chemicals, and
b) carrying out ATPS separation,
wherein the aqueous two-phase system is as defined in any one of claims 20 to 22.

25




Fig 1.

2/28




Fig 2.

3/28




Fig 3.

4/28




Fig 4.

5/28





Fig 5.

6/28

**Fig 6.**

7/28




Fig 7.

8/28




Fig. 8

9/28




Fig. 9

10/28




Fig. 10

09/936823

WO 00/58342

PCT/FI00/00249

11/28




Fig. 11

12/28




Fig 12.

09/936823

WO 00/58342

PCT/FI00/00249

13/28

1 2 3



Fig. 13

14/28




Fig 14.

15/28




Fig 15.




Fig. 16

WO 00/58342

PCT/FI00/00249

17/28




Fig. 17

18/28




Figure 18.

19/28




Figure 19

20/28




Figure 20.

21/28





Figure 21

22/28

**Figure 22**

23/28




Figure 23

24/28

Figure 24



25/28




Fig. 25

26/28




Fig. 26

WO 00/58342

PCT/FI00/00249

27/28




Figure 27

28/28




Figure 28

BIRCH, STEWART, KOLASCH & BIRCH, LLP

P.O. Box 747 • Falls Church, Virginia 22040-0747

Telephone: (703) 205-8000 • Facsimile: (703) 205-8050

ATTORNEY DOCKET NO.

0933 0170P

PLEASE NOTE:
YOU MUST
COMPLETE THE
FOLLOWING:



COMBINED DECLARATION AND POWER OF ATTORNEY FOR PATENT AND DESIGN APPLICATIONS

Insert Title: ➔

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated next to my name; that I verily believe that I am the original, first and sole inventor (if only one inventor is named below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

PROCESS FOR PARTITIONING OF PROTEINS

the specification of which is attached hereto. If not attached hereto,

Fill in Appropriate
Information — ➔
For Use
Without
Specification
Attached:

the specification was filed on _____ as
United States Application Number _____;
and amended on _____ (if applicable); and/or
the specification was filed on March 24, 2000 as PCT
International Application Number PCT/FI00/00249; and was
amended under PCT Article 19 on _____ (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I do not know and do not believe the same was ever known or used in the United States of America before my or our invention thereof, or patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to this application, that the same was not in public use or on sale in the United States of America more than one year prior to this application, that the invention has not been patented or made the subject of an inventor's certificate issued before the date of this application in any country foreign to the United States of America on an application filed by me or my legal representatives or assigns more than twelve months (six months for designs) prior to this application, and that no application for patent or inventor's certificate on this invention has been filed in any country foreign to the United States of America prior to this application by me or my legal representatives or assigns, except as follows.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 (a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

Insert Priority
Information:
(if appropriate) ➔

		Priority Claimed
99 0667	Finland	<input checked="" type="checkbox"/> <input type="checkbox"/> Yes No
(Number)	(Country)	
19991782	Finland	<input checked="" type="checkbox"/> <input type="checkbox"/> Yes No
(Number)	(Country)	
_____	_____	<input type="checkbox"/> <input type="checkbox"/> Yes No
_____	_____	<input type="checkbox"/> <input type="checkbox"/> Yes No

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

Insert Provisional
Application(s): ➔
(if any)

(Application Number)	(Filing Date)
_____	_____

All Foreign Applications, if any, for any Patent or Inventor's Certificate Filed More than 12 Months (6 Months for Designs) Prior to the Filing Date of This Application:

Insert Requested
Information:
(if appropriate) ➔

Country	Application Number	Date of Filing (Month / Day / Year)
_____	_____	_____

I hereby claim the benefit under Title 35, United States Code, §120 of any United States and/or PCT application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States and/or PCT application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Insert Prior U.S.
Application(s): ➔
(if any)

(Application Number)	(Filing Date)	(Status — patented, pending, abandoned)
_____	_____	_____

I hereby appoint the following attorneys to prosecute this application and/or an international application based on this application and to transact all business in the Patent and Trademark Office connected therewith and in connection with the resulting patent based on instructions received from the entity who first sent the application papers to the attorneys identified below, unless the inventor(s) or assignee provides said attorneys with a written notice to the contrary:

16 -

Raymond C. Stewart	(Reg. No. 21,066)	Terrell C. Birch	(Reg. No. 19,382)
Joseph A. Kolasch	(Reg. No. 22,463)	James M. Slattery	(Reg. No. 28,380)
Bernard L. Sweeney	(Reg. No. 24,448)	Michael K. Mutter	(Reg. No. 29,680)
Charles Gorenstein	(Reg. No. 29,271)	Gerald M. Murphy, Jr.	(Reg. No. 28,977)
Leonard R. Svensson	(Reg. No. 30,330)	Terry L. Clark	(Reg. No. 32,644)
Andrew D. Meikle	(Reg. No. 32,868)	Marc S. Weiner	(Reg. No. 32,181)
Joe McKinney Muncy	(Reg. No. 32,334)	John A. Castellano	(Reg. No. 35,094)
Donald J. Daley	(Reg. No. 34,313)	John W. Bailey	(Reg. No. 32,881)

Send Correspondence to:

BIRCH, STEWART, KOLASCH & BIRCH, LLP or **Customer No. 2292**

P.O. Box 747 • Falls Church, Virginia 22040-0747

Telephone: (703) 205-8000 • Facsimile: (703) 205-8050

PLEASE NOTE:
YOU MUST
COMPLETE
THE
FOLLOWING:

Full Name of First or
Sole Inventor:
→
Insert Name of
Inventor
Insert Date This
Document is Signed
↓
Insert Residence
Insert Citizenship
→
Insert Post Office
Address
→
Full Name of Second
Inventor, if any:
see above
200

GIVEN NAME	FAMILY NAME	INVENTOR'S SIGNATURE	DATE*
Merja	PENTTILA	<i>Merja Penttilä</i>	6th Sept 2001
Residence (City, State & Country)		CITIZENSHIP	
Helsinki, Finland		Finnish	

POST OFFICE ADDRESS (Complete Street Address including City, State & Country)

Vattuniemenkatu 2 A 22, FIN-00210 HELSINKI, FINLAND

GIVEN NAME	FAMILY NAME	INVENTOR'S SIGNATURE	DATE*
Tiina	NAKARI-SETÄLÄ	<i>Tiina Nakari-Setälä</i>	6th Sept 2001
Residence (City, State & Country)		CITIZENSHIP	
Espoo, Finland		Finnish	

POST OFFICE ADDRESS (Complete Street Address including City, State & Country)

Magnus Enckellin kuja 2-4 D 7, FIN-02610 ESPOO, FINLAND

GIVEN NAME	FAMILY NAME	INVENTOR'S SIGNATURE	DATE*
Richard	FAGERSTRÖM	<i>Richard Fagerström</i>	6th Sept 2001
Residence (City, State & Country)		CITIZENSHIP	
Espoo, Finland		Finnish	

POST OFFICE ADDRESS (Complete Street Address including City, State & Country)

Kielotie 18 A, FIN-02260 ESPOO, FINLAND

GIVEN NAME	FAMILY NAME	INVENTOR'S SIGNATURE	DATE*
Klaus	SELBER	<i>Klaus Selber</i>	17-09-01
Residence (City, State & Country)		CITIZENSHIP	
Aachen, Germany		German	

POST OFFICE ADDRESS (Complete Street Address including City, State & Country)

Pontstrasse 153, D-52062 AACHEN, GERMANY

GIVEN NAME	FAMILY NAME	INVENTOR'S SIGNATURE	DATE*
Maria-Regina	KULA	<i>Maria-Regina Kula</i>	11-09-01
Residence (City, State & Country)		CITIZENSHIP	
Niederzier, Germany		German	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country)			
Selgenbusch 12, D-52382 NIEDERZIER, GERMANY			

* DATE OF SIGNATURE

Full Name of Sixth Inventor, if any:
see above

6-00

GIVEN NAME/FAMILY NAME		INVENTOR'S SIGNATURE	DATE*
<u>Markus</u> <u>LINDER</u>		<i>M. Linder</i>	6/9-01
Residence (City, State & Country)		CITIZENSHIP	
<u>Helsinki</u> , Finland <u>FIX</u>		Finnish	

Full Name of Seventh Inventor, if any:
see above

7-00

GIVEN NAME/FAMILY NAME		INVENTOR'S SIGNATURE	DATE*
<u>Folke</u> <u>TJERNELD</u>		<i>Folke</i>	3/10-01
Residence (City, State & Country)		CITIZENSHIP	
<u>Limhamn</u> , Sweden <u>SEX</u>		Swedish	

Full Name of Eighth Inventor, if any:
see above

8-00

GIVEN NAME/FAMILY NAME		INVENTOR'S SIGNATURE	DATE*
Residence (City, State & Country)		CITIZENSHIP	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country)			
Stenshuvudsgatan 29, SE-216 17 LIMHAMN, SWEDEN			

Full Name of Ninth Inventor, if any:
see above

9-00

GIVEN NAME/FAMILY NAME		INVENTOR'S SIGNATURE	DATE*
Residence (City, State & Country)		CITIZENSHIP	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country)			

Full Name of Tenth Inventor, if any:
see above

10-00

GIVEN NAME/FAMILY NAME		INVENTOR'S SIGNATURE	DATE*
Residence (City, State & Country)		CITIZENSHIP	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country)			

Full Name of Eleventh Inventor, if any:
see above

11-00

GIVEN NAME/FAMILY NAME		INVENTOR'S SIGNATURE	DATE*
Residence (City, State & Country)		CITIZENSHIP	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country)			

Full Name of Twelfth Inventor, if any:
see above

12-00

GIVEN NAME/FAMILY NAME		INVENTOR'S SIGNATURE	DATE*
Residence (City, State & Country)		CITIZENSHIP	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country)			

*DATE OF SIGNATURE

09/936823

JC16 Rec'd PCT/PTO SEP 18 2001

WO 00/58342

PCT/FI00/00249

1

SEQUENCE LISTING

<110> Valtion teknillinen tutkimuskeskus

<120> Process for partitioning of molecules

<130> 31805

<140>

<141>

<160> 42

<170> PatentIn Ver. 2.2

<210> 1

<211> 428

<212> DNA

<213> *Trichoderma reesei*

<220>

<221> intron

<222> (167)..(236)

<220>

<221> intron

<222> (323)..(386)

<220>

<223> Coding sequence of *hfb1*

<400> 1

atgaagtttct tcgccccatcgcc cgctctcttt gcccggcgctg
gaccgcagca acggcaacgg caatgtttgc cttcccgcc
tgtgccaccc aagtctttgg cctcatcgcc cttgactgca
aacataagaa tcctcttgcac gggaaatatgc cttctactc
ccagaacgtt tacgacggca ccgacttccg caacgtctgc
tctctgtctgc gtggccccccg ttgtaaatgtt atgccccagc
aacccttacccatc gacaccaga ctgcaggccg gccaggctct
gtgtttga

<210> 2

<211> 78

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCT

<400> 2

ccgggcacta cgtgccagta tagcaacgac tactactcgc a
ccttagttctg gaaccgca

<210> 3
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR 3' primer

<400> 3
tcgtacggat cctcaaggcac cgacggcggt

30

<210> 4
<211> 63
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR 5' primer

<400> 4
actacacgga ggagctcgac gacttcgagc agcccgagct gcacgcagag caacggcaac 60
ggc 63

<210> 5
<211> 2211
<212> DNA
<213> *Trichoderma reesei*

<220>
<221> promoter
<222> (1)..(2211)
<223> *cbh1* promoter sequence

<400> 5
gaattctcac ggtgaatgta ggcctttgtt agggtaggaa ttgtcactca agcaccccca 60
acctccatta cgcctcccc atagagttcc caatcagtga gtcattggcac tggctcaaa 120
tagattgggg agaagttgac ttccggccag agctgaaggt cgcacaacccg catgatata 180
ggtcggcaac ggcaaaaaag cacgtggctc accggaaagc aagatgttt cgatctaaca 240
tccaggaacc tggatacatc catcatcactc cacgaccact ttgatctgct ggttaactcg 300
tatcgccctt aaaccgaagt gctgtgtaaa tctacacgtg ggcgccttc ggtataactgc 360
gtgtgtcttc tcttaggtgca ttctttctt cctctagtgt tgaattgtt gtgttggag 420
tccgagctgt aactacctt gaatctctgg agaatgtgtt actaacacact accgtgcacc 480
tgcatacatgt atataatagt gatcctgaga aggggggtt ggagcaatgt gggactttga 540
tggcatcaa acaaagaacg aagacgctc ttttgcggaa ttttgcggaa gctacggtg 600
agaactggat acttgttgcg tcttctgtgtt atttttgtgg caacaagagg ccagagacaa 660
tctattcaaa caccacgtt gctcttttga gctacaagaa cctgtgggtt atataatctgt 720
agttgtgaag tcggtaatcc cgctgtatag taatacgtatgt cgcataaaa tactccgaag 780
ctgctgcgaa cccggagaat cgagatgtgc tgaaagctt ctgcgcggc gctaaatttg 840
catgaaaggc tatgagaaat tctggagacg gctgtgtgaa tcatggcggtt ccattttcg 900
acaagcaaag cggtccgtcg cagtagcagg cactcattcc cggaaaaact cggagattcc 960
taatgtcgta tggaaaccggaa ataataat aggcaataca ttgagttgcc tcgacgggtt 1020
caatgcagggtt gtaactgagct tggacataac tggccgtac cccacctt ctcacaccc 1080
ggcggttccc tgattcagcg taccggataac agtgcgtatc actattaacc cagactgacc 1140
ggacgtgtt tgcccttcat ttggagaaat aatgtcattt gatgtgttaa tttgcctgct 1200
tgaccgactg gggctgttcg aagcccgaaat gtggattgtt atccgaact ctgctcgtag 1260
aggcatgttgc tgaatctgtg tcggccagga cacgcctcgaa aggttccacgg caagggaaac 1320

caccgatagc agtgtctagt agcaacctgt aaagccgcaa tgcagcatca ctggaaaata 1380
caaaccaatg gctaaaagta cataagtaa tgcctaaaga agtcatatac cagcggctaa 1440
taattgtaca atcaagtggc taaacgtacc gtaatttgc aacgcgttg ggggttgcag 1500
aagcaacggc aaagccact tcccacgtt gtttcttac tcagtccaaat ctcagctgg 1560
gatccccaa ttgggtcgct tgtttgc tggtaagtga aagaagacag agttaagaat 1620
gtctgactcg gagcgttttgc catacaacca agggcagtga tggaaagacag tggaaatgtt 1680
acatccaagg agtattttgc cagggatgtc tgagtgtatc gtgttaaggag gtttgtctgc 1740
cgatacgacg aatactgtat agtcactt gatgaagtgg tccatattga aatgttaagtc 1800
ggcactgaac aggcaaaaaga ttgagttgaa actgcctaag attcggggcc ctcgggcttc 1860
ggcttgggt gtacatgtt gtgctccggg caaatgcaaa gtgtggtagg atcgacarac 1920
tgctgcctt accaaggcagc tgagggatgtc tgataggcaa atgttcaggg gccactgcat 1980
ggtttcgaat agaaaagagaa gcttagccaa gaacaatagc cgataaaagat agcctcatta 2040
aacgaaatga gctagtaggc aaagtcagcg aatgtgtata tataaaagggtt cgaggtccgt 2100
gcctccctca tgctctcccc atctactcat caactcagat cctccaggag acttgtacac 2160
catctttga ggcacagaaaa cccaatagtc aaccggggac tgccatcat g` 2211

<210> 6

<211> 1588

<212> DNA

<213> *Trichoderma reesei*

<220>

<223> *T. reesei* egli cDNA

<400> 6

ccccctatc ttagtccttc ttgttgtccc aaaatggcgc cctcagttac actgccgttg 60
accacggcca tcctggccat tgcccggtc gtgcggccc agcaaccggg taccagcccc 120
cccgagggtcc atccccaaat gacaacctac aagtgtacaa agtccggggg gtgcgtggcc 180
caggacacct cgggtgtctc tgactggaaac taccgtctgg tgcacgcacgc aaactacaac 240
tcgtgcaccc tcaacggccg cgtcaacac acgctctggc ctgacgcggc gacctgtggc 300
aagaactgtc tcatcgaggg cgtcgactac gcccgtctgg gctgtcacgc ctccggcagc 360
agcctcacca tgaaccagta catgcccggc agctctggcg gctacagcag cgtctctct 420
cggtgtatac tcctggactc tgacgggtgag tacgtgtatgc tgaagctcaa cggccaggag 480
ctgagcttcg acgtcgaccc ctctgtctc ccgtgtggag agaaacggctc gctctacctg 540
tctcagatgg acgagaacgg gggcgccaaac cagtataaca cggccgggtgc caactacggg 600
agcggctact gcgatgtca gtgccccgtc cagacatggaa ggaacggcac cctcaacact 660
agccaccagg gtttctgtcg caacgagatg gatattctgg agggcaactc gagggcgaat 720
gccttgcaccct tcactcttcg cacggccacg gcctgcgact ctgcccgttg cggcttcaac 780
ccctatggca gcccgtacaa aagctactac gggccggag ataccgttga cacctccaag 840
accttcacca tcatcacccca gttcaacacg gacaacggct cggccctcggg caacccttgg 900
agcatcacccca cgaagatcca gcaaaacggc gtcgacatcc ccagcgccca gcccggcggc 960
gacaccatct cgtctctggcc gtcggccatca gcctacggcg gcctcgccac catgggcaag 1020
gccttgcacca gcccgtatggt gtcgtgttc agcatttggaa agcacaacag ccagtatcatg 1080
aactggctcg acagcggcaa cggccggcccc tgcagcagca ccgagggcaa cccatccaac 1140
atccctggccca acaaccccaa cacgcacgtc gtcttctcca acatccgtcg gggagac .t 1200
gggtctacta cgaactcgac tgcggccccc ccccccgtcg cgtccagcac gacgttttcg 1260
actacacggc ggagctcgac gacttcgagc agcccggatc gcacgcagac tcactgggg 1320
cagtgcgggtc gcattgggtt cagcgggtgc aagacgtca cgtcgggcac tacgtggccag 1380
tatagcaacg actactactc gcaatgcctt tagagcgttg acttgcctct ggtctgtcca 1440
gacggggggca cgatagaatg cgggcacgca gggagctcg agacattggg cttaatatat 1500
aagacatgtc atgttgtatc tacattagca aatgacaaac aaatgaaaaaa gaacttatca 1560
agcaaaaaaaaaaaaaaaa aaaaaaaaaaaaaaaa 1588

<210> 7
<211> 745
<212> DNA
<213> *Trichoderma reesei*

<220>
<221> terminator
<222> (1)..(745)
<223> *T. reesei cbh1* terminator

<400> 7
ggacctaccc agtctcaacta cggccagtgc ggcggatttgc gctacagcgg ccccacggc 60
tgcgcacgcg gcacaacttgc ccaggctctg aacccttact actctcagtgc cctgtaaagc 120
tccgtgcgaa agcctgacgc accggtagat tcttggtgag cccgtatcat gacggcggcg 180
ggagctacat ggccccgggt gatttatttt ttttgtatct acttctgacc cttttcaaat 240
atacggtaaa ctcatcttc actggagatg cggcctgcgtt ggtattgcga tgggtcagc 300
ttggcaaattt gtggctttcg aaaaacacaaa acgattccctt agtagccatg catttaaga 360
taacggaata gaagaaagag gaaattaaaa aaaaaaaaaa aacaaacatc cccgttctaa 420
cccgtagaat cggcgtctt cgtgtatccc agtaccacgt caaaggattt catgatcggt 480
caatgttcat atttttccgc cagtaggcgtt ccaccccat cttccgcgaaat ctcctttct 540
cgaacgcgggt agtggctgtc gccaatttggt aatgaccata gggagacaaa cagcataata 600
gcaacagtgg aaatttagtgg cgcaataatt gagaacacag tgagaccata gctggcggcc 660
tgaaaaagcac tggggagac caacttgtcc gttgcgaggc caacttgcat tgctgtcaag 720
acgatgacaa cgtagccgag gaccc 745

<210> 8
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: annealed primer

<400> 8
taaccgcgggt

10

<210> 9
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: annealed primer

<400> 9
ctagaccgcgcgtttaat

16

<210> 10
<211> 1232
<212> DNA
<213> *Trichoderma reesei*

<220>
<221> promoter
<222> (1)..(1232)

<223> *T. reesei* *gpd1* promotor

<400> 10

<210> 11

<211> 1129

<212> DNA

<213> *Trichoderma reesei*

<220>

<221> terminator

<222> (1) .. (1129)

<223> T. reesei qpd1 terminator

<400> 11

```

ggatcccgag cattgtctat gaatgcaaac aaaaatagta aataaatagt aattctggcc 60
atgacgaata gagccaatct gctccacttg actatcttgc gactgtatcg tatgtcgaac 120
ccttgcgtgc ccattcaaac aattgtaaag gaatatagtt acaagttatg tctcacgttt 180
gcgtgcgagc ccgttggatc gtatggatc gaaagcgttg ccatacacatg ctcacagtc 240
cttggcttac gatcatgttt gcgtatctcg gtaagaatac acagagtaac gattatctcc 300
atcgcttcta tgatttagta ctcagacaac acatggggaa caagataacc atcgcatgca 360
aggtcgattt caatcatgtat ctggactggg gtattccatc taagccatag taccctctcg 420
agaaggaaatg gtaggaccc tcagggcgtcc accatctgtg ctgcaatcc aagaaacccc 480
ccaaaagcac ctacatccatc accttagagta actgcacgag aaaagaaaaag gaggcagaaga 540
agaatgatctt caagaggccg tgaacgcaga aacacactcc tcccaacttt tcaagtttt 600
aaaaaaaaaaa gaaagatgtag gactagaaga tggagtttt ccttctttaga gagctctcg 660
tgaggtgacc tgcgtgggtt taccgcggac cgtccgtgt tctatccat taatcaagtc 720
ccgcgcctcg ccttttttctt cctgtcttccatc catagaatcc cgtctccctt ttgtttgatc 780
gaagcggggtt tatcgacgccc accaaaagatc ttgtcttgc gacttatca tcccttgggt 840
atcaaacagc ccccgagtga tcagatccgtt aaaaagaagaa gaagagttacg attaaccag 900
accgaggaaac aataaaagcga gtaaataaca tcaaaaataag agtctcggtt aaaattactt 960
gttccctcaat caatccccaaac ccccccataaa gcccctccccc ccatggatata tcccccggcagt 1020
aggagagaga tattttccact accgctcacc accaagttag gcttggcgag agaagaggat 1080
gaatcagaag tgacaacaac ggggttggatc catgggatata cggccggcc 1129

```

<210> 12
<211> 5733
<212> DNA
<213> *Aspergillus nidulans*

<220>
<223> (1-5733) Sequence of plasmid pAN52-1

<220>
<221> promoter
<222> (1)..(2129)
<223> *A. nidulans gpdA* promoter

<220>
<221> gene
<222> (2130)..(2304)
<223> *A. nidulans gpdA* gene

<220>
<221> terminator
<222> (2305)..(3071)
<223> *A. nidulans trpC* terminator

<220>
<221> misc_feature
<222> (3072)..(5726)
<223> pUC18 from SalI to EcoRI

<400> 12
caattccctt gatatctac acacaggctc aaatcaataa gaagaacggt tcgtctttt 60
cgtttatata ttgcatacg tc aaagctat tggcggata ttctgtttgc agttggctga 120
cttgaagtaa tctctgcaga tctttcgaca ctgaaatacg tcgagcctgc tccgcttgg 180
agccgcgagg agcctcgccc tgcataact accaacatgg agtacgataa gggccagtcc 240
cgccagctca ttaagagcca gttcatgggc gttggcatga tggccgtcat gcatctgtac 300
ttcaagtaca ccaacgctct tctgtatcccg tcgatcatcc gctgaaggcg ctttcaatc 360
tggtaagat ccacgtcttc gggaaagcccg cgactggtaa cctccagcgt ccctttaagg 420
ctgccaacag ctttctcagc caggcccagg ccaagaccga caaggccccc ctccagaacg 480
ccgagaagaa ctggagggggt ggtgtcaagg aggagtaagc tccttattga agtcggagga 540
cgagccgtg tcaagaggat attcttcgac tctgtattat agataagatg atgaggaaatt 600
ggaggttagca tagcttcatt tggatttgct ttccaggctg agactctagc ttggagcata 660
gagggtccctt tggctttcaa tattctcaag tatctcgagt ttgaacttat tccctgtgaa 720
ccttttattc accaatgagc attggaatga acatgaatct gaggactgca atccatgc 780
ggtttcgaa atacatccgg atgtcgaagg ctggggcac ctgcgttgg tgaattttaga 840
acgtggact attgatcatc cgatagctc gcaaaaggcg ttgcacaatg caagtcaaac 900
gttgcgtaca gttccagggtg gaatgtatg atgagcattt tattaaatca ggagatata 960
catatctct agttatcgcc caacaaaatg cagacggcgt aaccaaaatg cacacaacac 1020
aagctgtaa gatttcggca cggctacggaa agacggagaa gcccattca gtggactcga 1080
gtaccattta attctatttt tggatgtcg agacctaata cagccccatc aacgaccatc 1140
aaagtcgtat agtctaccatg gaggaaatgg actctaaatcg acttcagcaa catctctgg 1200
ataaaacttta agcctaaact atacagaata agataggatgg agagcttata ccgagctccc 1260
aaatctgtcc agatcatggt tgaccggcgc ctgatcttc ctatagaatc atccttattc 1320
gttgcgtatc ctgatctgg agtgaccatg agggtcatga ctggatgttca aaatccggc 1380
cctccaccat ttgttagaaaa atgtgacgaa ctgtgatgtt ctgtacatgtt accgggtact 1440
ctttctggca tgcggagaga cggacggacg cagagagaag ggctgatgttta taagccactg 1500
gccagacgc tctggcggcgt ctgaggtgca gtggatgtt attaattccgg gaccggccgc 1560
ccctccccc cgaagtggaa aggctgtgtt gcccctcgat gaccaagaat ctattgcata 1620
atcggagaat atggagcttc atcgaatcac cggcgtatgg cgaaggagaa tgcgtatggca 1680
gggggtgtata ggcgtcggcgc aaatagcatg ccattaaacctt aggtacagaa gtccaaattgc 1740

ttccgcgtatcg gtaaaaagatt caccggatag taccttctcc gaagtaggta gagcgagtag 1800
ccggcgcgta agctccctaa ttggcccatc cggcatctgt agggcggtca aatatcggtc 1860
ctctccgtct ttgccccgtg tatgaaaccg gaaaggccgc tcaggagctg gccagcgcg 1920
cagaccggga acacaagctg gcagtcgacc catccgggtc tctgcactcg acctgctgag 1980
gtccctcagt ccctggtagg cagcttgcg ccgtctgtcc gcccgggtgtg tcggcggggt 2040
tgacaaggtc gttcgctcag tccaacattt gttgcacat tttccgtctc tccccaccag 2100
ctgctctttt ctttctttt tctttccca tcttcagttt attcatctt ccatccaaga 2160
accttttattt cccctaagta agtactttgc tacatccata cttccatctt cccatccctt 2220
attccttga acctttcagt tcgagcttgc ccacttcattt gcagcttgcg taacagctac 2280
cccgcgttagg cagacatcac catggatcca cttaaacgtt ctgaaatcat caaacagctt 2340
gacgaatctg gatataagat cgttgggtc gatgtcagct cccggagttga gacaaatgg 2400
gttcaggatc tcgatagat acgttcatc gtccaaagcgaa caaagagttgc cttctagtg 2460
ttaatagct ccatgtcaac aagaataaaa cgcgtttcg ggtttacctc ttccagatc 2520
agctcatctg caatgcattt atgcatttgc tgcaacccgt taacgcctt caggctccgg 2580
cgaagagaag aatagcttag cagagctt cttatcttgc ggagacgaga tcaagcagat 2640
caacggctgt caagagacct acggagactga ggaatccgc cttggcttca cgcgactata 2700
tattttgtctc taattgtact ttgacatgt cctcttctt actctgtatc ttgtact 2760
aaaatccgt caccagcncc tgggttcgca aagataattt catgttttcc cttgttaactc 2820
tcaagcctac aggacacaca ttcatcgtag gtataaacct cggaaatccatc tccatctt 2880
atggtataca atagtaacca tgcattgggtt cctagtgtat gctccgttac acccaatacg 2940
ccggccgaaa ctttttaca actctcttat ggtcgatc cccagaatgc acaggtaac 3000
ttgttagag gtaatccctt cttcttagaaag tccctgttgc ctgtgttaactc gcccacttca 3060
catctccact cgacccgtcag gcatgtcaagc ttggacttgc cctgtgtttt acaacgtcgt 3120
gactggggaaa accctggcgt tacccttacccat aatccgttgc cagcacatcc cccttcgccc 3180
agctggcgtt atagcgaaatggccgat gggccgcacc gatcgccctt cccaaacagtt ggcgagccgt 3240
aatggcgtt ggcgcgtat ggcgttattttt ctccttacgc atctgtgcgg tattttcacac 3300
cgcatatggt gcacttcgtc tacaatctgc tctgtatccgg catagttaa ccagccccga 3360
caccggccaa caccggctga cggcccttgc cgggcttgc tgctcccgcc atccgcttac 3420
agacaagctg tgaccgttgc cggggacttgc atgtgtcaga ggttttccacc gtcatcacc 3480
aaacgcgcga gacggaaagggttctgttgcata cgccttattttt tataaggtaa tgcattgtata 3540
ataatgggtt ctttagacgtc aggtggactt ttcggggaa atgtgcgcgg aacccttattt 3600
tggttattttt tctaaataca tccaaatatgt ttcggctca tgagacaata accctgtat 3660
atgccttcaat aatattgaaa aaggaagatc atgatattc aacatttccg tgcgtccctt 3720
attccctttt ttggccgttgcatt ttgccttccctt gtttttgc accccggaaac gctgggtgaaa 3780
gtaaaaagatg ctgaagatca gttgggtca cggatgggtt acatcgaaact ggatctcaac 3840
agcggtttaaga tccttggagag ttttcggccc gaagaacgtt ttccaatgtt gggactttt 3900
aaagttctgc tatgtggcgc ggtattatcc cgtatttgc cccggcaaga gcaactcgtt 3960
cgccgcatac actattctca gaatgacttgc gttgagttact caccaggtaac agaaaagcat 4020
cttacggatg gcatgacagt aagagaattt tgcatgtgc ccataaccat gaggatgtttt 4080
actgcggcca acttacttgc gacaacgttgc ggaggaccga aggagcttac cgtttttttt 4140
cacaacatgg gggatcatgt aacttcgttgc gatcggttgg aaccggagct gaatgaagcc 4200
ataccaaaacg acgagcgttgc caccacgtatg cctgtatcga tggcaacaac gttgcgc 4260
cttataactg gcgactact tactcttagt tccggcaac aattaataga ctggatggag 4320
gcggataaag ttgcaggacc acttctgcgc tcggcccttc cggctggctg gttttattgt 4380
gataaaatctg gagccgttgc ggcgtgggtct cgggtatca ttgcagactt gggggccat 4440
ggtaaggccctt cccgtatctgt agttatcttgc acgacggggta gtcaggtaac tatggatgaa 4500
cgaaaatagac agatcgctga gatagggttgc tcaactgttgc agcatggta actgtcagac 4560
caagtttactt catatataactt ttagattgtt taaaaacttcc attttaattt taaaaggatc 4620
taggtgaaga tccttttgc taatctcatg accaaaaatcc cttaaacgttgc gttttcggtt 4680
caactgacgtt cagacccctgtt agaaaagatc aaaggatctt ctgttgcactt ttttttctg 4740
cgctaatctt gtcgttgc ttttttttttgc aacaaaaaaa ccacccgttgc cgggggtgtt ttgttgcgg 4800
gatcaagagc taccaacttct tttccgttgc gtaactggct tcagcagacgc gcagatacc 4860
aataactgtcc ttcttagtgc gccgtatgtt ggcggccactt ctaagaactc tgcgtccgg 4920
cctacatacc tgcgttgc ttttttttttgc aatccgttgc ccagtggctg ctgcggacttgc cgataagtgc 4980
tgtcttaccg ggttggacttgc aagacgtatgttgc ttaccggata agggccggcc gtcggggctg 5040
acgggggggtt cgtgcacaca gcccagtttgc gggccggccactt cttacaccga actggat 5100
ctacagcggttgc agctatgaga aagccggccactt cttccggata gggaaaaggc ggacaggat 5160
ccggtaagcg gcagggttgc aacaggagag cgcacgggg agcttccaggq qggaaaaccc 5220

tggtatctt atagtcctgt cgggtttcgc cacctctgac ttgagcgtcg attttgtga 5280
tgcctcgtag gggggcggag cctatggaaa aacgccagca acgcggcctt ttacgggttc 5340
ctggcctttt gctggcctt tgctcacatg ttcttcctg cgttatcccc tgattctgtg 5400
gataaccgtta ttaccgcctt tgagtggact gataccgctc gccgcagccg aacgaccgag 5460
cgccgcgagt cagtggcgtc ggaaggcgaa gagcgcggaa tacgcaaacc gcctctcccc 5520
gcgcgttggc cgattcatta atgcagctgg cacgacagggt ttcccgactg gaaagcgggc 5580
agtggcgca acgcaattaa tgtgagttt ctcactcatt aggcacccca ggctttacac 5640
tttatgttcc cggtcgat gttgtgtgaa attgtgagcg gataacaatt tcacacagga 5700
aacagctatg accatgatta cgaattgcgg ccg 5733

<210> 13

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR 5' primer

<400> 13

gtcaaccgcg gactgcgcatt catgaaggttc ttccgcattc

39

<210> 14

<211> 66

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR 5' primer

<400> 14

tctagcaaggc ttggctctag ttctggaaacc gcaccaggcg gcagcaacgg caacggcaat 60
gtttgc 66

<210> 15

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR 3' primer

<400> 15

tcgtacaaggc tttcaaggcac cgacggcggt

30

<210> 16

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR 5' primer

<400> 16

tctagctcta gaagcaacgg caacggcaat gtt

33

<210> 17
<211> 37
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR 3' primer

<400> 17

tgcttagtgc cctgctagca gcacccgacgg cggtctg

37

<210> 18
<211> 4614
<212> DNA
<213> *Saccharomyces cerevisiae*

<220>

<223> *S. cerevisiae* *FLO1* coding sequence

<400> 18

atgacaatgc ctcatcgcta tatgttttg gcagtcttta cacttctggc actaactagt 60
gtggcctcag gagccacaga ggcgtgccta ccagcaggcc agaggaaaag tggatgaat 120
ataaaattttt accagtattc attgaaagat tcctccacat attcgaatgc agcatatatg 180
gcttatggat atgcctaaa aaccaaacta gttctgtcg gaggacaaac tgatatctcg 240
attgattata atattccctg tgtagttca tcagggcacat ttcttgc tcaagaagat 300
tcctatggaa actggggatg caaaggaaatg ggtgcttgc ttaatagtca aggaattgca 360
tactggagta ctgattttt tggttctat actaccccaa caaacgtaac cctagaatg 420
acagggttatt ttttaccacc acagacgggt tcttacacat tcaagttgc tacagttgac 480
gactctgcaa ttctatcagt aggtggtgca accgcgttca actgttgc tcaacagcaa 540
ccgcgcgtatca catcaacgaa cttaaccatt gacggtatca agccatgggg tggaaagtgg 600
ccacctaata tcgaaggaaac cgtctataatg tacgctggct actattatcc aatgaagggt 660
gtttaactcg aacgctgttcc ttgggttaca cttccaaatg tgtagacact tccagatgg 720
accactgtaa gtgatgactt cgaagggtac gtcttacat ttgacgatga cctaagtcaa 780
tctaactgtatcgatccatcataat tataatgtca gtaccatcact aactacaacg 840
gaaccatggaa ccggtaactt cacttctaca tctactgaaa tgaccaccgt caccggtacc 900
aacggcggttc caactgacga aaccgtcatt gtcatacgaa ctccaaacaaac tgctagcacc 960
atataacta caactgagcc atgaaacagc acttttacat ctacttctac cgaattgacc 1020
acagtcaactg gcaccaatgg tgcataactt gacaaaccca tcattgtaaat cagaacaccca 1080
acaacagccca ctactgcatca aactacaact gacccatggaa acagcacttt taccttact 1140
tctaccgaat tgaccacagt caccggtaacc aatgggttgc caactgatga gaccatcatt 1200
gtcatacgaa caccacaaac agccactact gccatgacta caactcagcc atgaaacgac 1260
acttttacat ctacatccac tggatgacc accgtcaccg gtaccaacgg tttgccaact 1320
gatgaaacca tcattgtcat cagaacacca acaacacggca ctactgatcat gactacaact 1380
cagccatggaa acgacactt taccttacat tccactgaaa tgaccaccgt caccggtacc 1440
aacgggttgc caactgatga aaccatcatt gtcatacgaa caccacaaac agccactact 1500
gccatgacta caactcagcc atgaaacgac acttttacat ctacatccac tggaaatgacc 1560
accgtcaccg gtaccaatgg tttgccaact gatgagacca tcattgtcat cagaacaccca 1620
acaacagccca ctactgcatca gactacaact caccatggaa acgacacttt taccttacat 1680
tccactgaaa tgaccaccgt caccggtaacc aacgggttgc caactgatga aaccatcatt 1740
gtcatacgaa caccacaaac agccactact gccatgacta caactgatccca atgaaacgac 1800
acttttacat ctacttctac cgaattgacc acagtccaccg gtaccaatgg tttgccaact 1860
gatgagacca tcattgtcat cagaacacca acaacacggca ctactgcat gactacaact 1920
cagccatggaa acgacactt taccttacat tccactgaaa tgaccaccgt caccggtacc 1980
aacgggttgc caactgatga aaccatcatt gtcatacgaa caccacaaac agccactact 2040
gccatgacta caactcagcc atgaaacgac acttttacat ctacatccac tggaaatgacc 2100
accgtcaccg gtaccaacgg tttgccaact gatgagacca tcattgtcat cagaacaccca 2160

acaacagcca ctactgccat gactacaact cagccatgga acgacactt tacctctaca 2220
tccactgaaa tgaccacgt caccggtaacc aacggcggtt caactgacga aaccgtcatt 2280
gtcatcagaa ctccaaactag tgaaggtcta atcagcacca ccactgaacc atggactggt 2340
actttcacct ctacatccac tgagatgacc accgtcaccg gtactaacgg tcaaccaact 2400
gacgaaaccg tgattgttat cagaactcca accagtgaag gtttggttac aaccaccact 2460
gaaccatgga ctggtacttt tactctaca tctactgaaa tgaccacat tactggaacc 2520
aacggcggtt caactgacga aaccgtcatt gtcatcagaa ctccaaaccag tgaaggtcta 2580
atcagcacca ccactgaacc atggactggt acttttactt ctacatctac taaaatgacc 2640
accattactg gaaccaatgg tcaaccaact gacgaaaccg ttattgttat cagaactcca 2700
actagtgaag gtctaattcag caccacat gacccatgga ctggtaactt cacttctaca 2760
tctactgaaa tgaccacgt caccggtaacc aacggcggtt caactgacga aaccgtcatt 2820
gtcatcagaa ctccaaaccag tgaaggtcta atcagcacca ccactgaacc atggactggc 2880
actttcacct cgacttccac tgaggttacc accatcactg gaaccaacgg tcaaccaact 2940
gacgaaactg tgattgttat cagaactcca accagtgaag gtctaattcag caccacact 3000
gaaccatgga ctggtacttt cacttctaca tctgctgaaa tgaccacgt caccggtaact 3060
aacggtcaac caactgacga aaccgtgatt gttatcagaa ctccaaaccag tgaaggtttg 3120
gttacaacca ccactgaacc atggactggt acttttactt cgacttccac taaaatgtct 3180
actgtcactg gaaccaatgg cttgccaact gatgaaactg tcattgttgc taaaactcca 3240
actactgcca tctcatccag tttgtcatca tcatcttcag gacaaatcac cagctctatc 3300
acgtcttcgc gtccaaattat tacccttattc tacccttagca atggaactt tttgtattct 3360
tcctcagtaa ttctttcttc agtcaatttct tctcttattca ttctttcttc agtcatattct 3420
tcctcagta ttctttcttc tacaacaacc tccacttctca tattttctga atcatctaaa 3480
tcatccgtca ttccaaaccag tagtccacc tctgggttctt ctgagagcga aacgagttca 3540
gtctggttctg ttctttcttc ctcttttatttcttcttcatcatat ttcttcatat 3600
tcttcttcat cattaccact tgtttaccatg gcgacaacaa gccaggaaac tgctttttca 3660
ttaccacccg ctaccactac aaaaacgagc gaacaaacca ttgggttctt cgtgacatcc 3720
tgcgagtcctc atgtgtgcac tgaatccatc tcccctgcga ttgttccac agctactgtt 3780
actgttagcg gctgcacaac agagataacc acatggtgcc ctatttctac tacagagaca 3840
acaaagcaaa ccaaaggcc aacagagcaa accacagaaa caacaaaaca aaccacggta 3900
gttacaattt ttctttgtga atctgacgta tgctctaaga ctgctttcttcc agccattgtta 3960
tctacaagca ctgctactat taacggcggtt actacagaat acacaacatg gtgtcttatt 4020
tccaccacag aatcgaggca acaaacaacg cttagttaactg ttacttcttgc cgaatctgg 4080
gtgtgttccg aaactgcttc acctggcatt gtttgcacgg ccacggctac tttgtatgtat 4140
gttggttacccg tctatcttac atggaggccca cagactgcga atgaagatc tttgtcaactt 4200
aaaatgaaca gtgttcccg tgagacaaca accaaactt tagtgcgtga aacgactacc 4260
aatactgttag ctgtgagac gatttccatc actggagctg ctgagacgaa aacagtagtc 4320
accttcttcgc ttcaagatc taatcgcgt gaaacacaga cggcttccgc gaccgatgtg 4380
attgggtcaca gcagtagtgt ttgttcttgc tccgaaactg gcaacaccaa gagtctaaca 4440
agtccgggt tgtagtactat gtcgaacag cctcgtagca caccagcaag cagcatggta 4500
ggatatagtt cagcttctt agaatttca acgtatgtt gcaactggccaa cagcttactg 4560
ggcggttagt gtttaagtgt ttcttatttgc tggcaattat tttaa 4614

<210> 19
<211> 5857
<212> DNA
<213> *Saccharomyces cerevisiae* and *E. coli*

<220>
<221> promoter
<222> (1)..(452)
<223> *S. cerevisiae* GAL1 promoter

<220>
<223> (476-495) *E. coli* T7 promoter/priming site

<220>
<223> (502-601) *E. coli* multiple cloning site

gcctgactcc ccgtcgtgta gataactacg atacggggagc gcttaccatc tggcccccgt 1980
gctgcaatga taccgcgaga cccacgctca cggctccag atttatcagc aataaaccag 2040
ccagccgaa gggccgagcg cagaagtggt cctgcaactt tatccgcctc cattcagtct 2100
attaattgtt gccgggaagc tagagtaagt agtgcgcag ttaatagttt gcgcaacgtt 2160
gttggcattt ctacaggcat cgtgggtca ctctcgtcgt ttgttatggc ttcaattcagc 2220
tccgggttccc aacgatcaag gcgagttaca tgatccccca tggtgcaaa aaaagcggtt 2280
agctccttcg gtccctcgat cgttgcaga agtaagtgg ccccgagtgtt atcaactatg 2340
gttatggcact cactgcataa ttctcttact gtcatggcat cctgtaagatg ctttctgt 2400
actggtgagt actcaaccaa gtcattctga gaatagtgtt tgccgggacc gagttgtct 2460
tgccggcgt caatacggga taatagtgtt tcaacatagca gaactttaaa agtgcctatc 2520
atggaaaac gttctcggg gcgaaaactc tcaaggatct taccgcgtt gagatccagt 2580
tcgatgttaac ccactcggtc acccaactga tcttcagcat cttttactt caccagcggt 2640
tctgggttag aaaaaacagg aaggcaaaaat gccgcaaaaa agggataaaag ggcacacgg 2700
aaatgttga tactcataact cttccctttt aatgggttaa taactgatataat aatgggtt 2760
aagctctaat ttgtgagttt agtatacatg catttactta taatacagtt ttttagttt 2820
gctggccgca tcttcctaaa tatgttccccc agectgcgtt tctgttaacgt tcacccctca 2880
ccttagcat ccttccttgc gcaaataatgc ctcttccaaac aataataatg tcagatctg 2940
tagagaccatc atcatccacg gtcttataact gttgacccttcc ttgtcatctaa 3000
aaccacacc ggggtgcata atcaaccaaat cgtaaccttc atcttcctca cccatgtctc 3060
ttttagcaat aagacccata acaaaaatctt tgtagcttcc ttgtcatctaa 3120
tagtatatttcc tccagtagat agggagccct tgcatgacaa ttctgttaac atcaaaaaggc 3180
ctcttaggttcc tttgttact tcttcgtccg cctgttccaa accgctaaaca atacctgggc 3240
ccaccacacc gtgtgcattt gtaatgtctg cccattctgc tattctgtat acacccgcag 3300
agtaactgca tttgactgta ttaccaatgt cagcaattt tctgtctcg aagagtaaaa 3360
aattgtactt ggccgataat gctttagcg gcttaactgt gcccctcatg gaaaaatcag 3420
tcaagatatac cacatgtttt ttttagtaaac aaattttggg acctaataatc tcaactaact 3480
ccagtaattt cttgggtgta cgaacatcca gcatgatatt aaataatctt gcagacacag gacttaggtt tgctttcgt 3540
gtactgatattt aaataatctt gcagacacag atgttagctt cgacatgatt tatcttcgtt tctgtcgtt acacccgcag 3600
aattgtactt ggccgataat gctttagcg ttaaataatc ttttggcaattt catgtttttt tgtagcttcc 3660
ttaagtctgtt ctccttcctt cgttcttctt ttaaataatc ttttggcaattt catgtttttt tgtagcttcc 3720
ttcaaaagaaaa ccgaaatcaa aaaaaaaaat ttaaataatc ttttggcaattt catgtttttt tgtagcttcc 3780
ctagcttatac gatgataagc tgcataatgtt gataactatc ttttggcaattt catgtttttt tgtagcttcc 3840
ctagataactc cgtctactgt acgataacact gataactatc ttttggcaattt catgtttttt tgtagcttcc 3900
cttaccactc ttttggcaattt ctattgtcc ttttggcaattt catgtttttt tgtagcttcc 3960
ctatcttcgc gatgttagaa aacttagctg accttctacaa tggctgcccatttatttac ttttggcaattt catgtttttt tgtagcttcc 4020
tcaaaatcgc ttttggggata tacagcctaa ttttggcaattt catgtttttt tgtagcttcc 4080
tctgacttgtt taccatcat tgaattttga agatgtatgtt ttttggcaattt catgtttttt tgtagcttcc 4140
ttttagtttcg gttccgggaa aacttattgc acgtatctgtt ttttggcaattt catgtttttt tgtagcttcc 4200
atccccgggtt cattttctgc gttcccatct ttttggcaattt catgtttttt tgtagcttcc 4260
agcatctgtt cttcattttgc ttttggcaattt catgtttttt tgtagcttcc 4320
aaagaatctg agctgcattt ttacagaaca ttttggcaattt catgtttttt tgtagcttcc 4380
acgaagaatc ttttggcaattt catgtttttt tgtagcttcc 4440
acgaagaatc ttttggcaattt catgtttttt tgtagcttcc 4500
tttcaaaacaa agaatctgtt ttttggcaattt catgtttttt tgtagcttcc 4560
ttttagtttcg gttccgggaa aacttattgc acgtatctgtt ttttggcaattt catgtttttt tgtagcttcc 4620
ttttagtttcg gttccgggaa aacttattgc acgtatctgtt ttttggcaattt catgtttttt tgtagcttcc 4680
ttttagtttcg gttccgggaa aacttattgc acgtatctgtt ttttggcaattt catgtttttt tgtagcttcc 4740
ttttagtttcg gttccgggaa aacttattgc acgtatctgtt ttttggcaattt catgtttttt tgtagcttcc 4800
gtctcttgcattt aacttttgc actgttagtc ttttggcaattt catgtttttt tgtagcttcc 4860
tcttatttttctt cttccataaa aaaacgttca cttccacttcc cgcgttactt gattactagc 4920
gaagctgcgg gttccgggaa aacttattgc acgtatctgtt ttttggcaattt catgtttttt tgtagcttcc 4980
ggattgcgttca ttttggcaattt catgtttttt tgtagcttcc 5040
aattatgttgcattt aacttttgc actgttagtc ttttggcaattt catgtttttt tgtagcttcc 5100
ttttagtttcg gttccgggaa aacttattgc acgtatctgtt ttttggcaattt catgtttttt tgtagcttcc 5160
gttaatactgtt aacttattgc acgtatctgtt ttttggcaattt catgtttttt tgtagcttcc 5220
cgaaagggttttgcattt aacttttgc actgttagtc ttttggcaattt catgtttttt tgtagcttcc 5280
cttttggcaattt aacttttgc actgttagtc ttttggcaattt catgtttttt tgtagcttcc 5340
tcagaaaagc cccaaaaacaa ggaagattgtt ataaatgttca ttttggcaattt catgtttttt tgtagcttcc 5400

tattttgtta aaattcgcgt taaaattttgc taaaatcagc tcattttta acgaatagcc 5460
cgaaaatccgc aaaatccctt ataaatcaaa agaatagacc gagataggt tgagtgttgc 5520
tccagttcc aacaagagtc cactattaaa gaacgtggac tccaaacgtca aaggcgaaa 5580
aagggtctat cagggcgatg gcccaactacg tgaaccatca ccctaataa gtttttggg 5640
gtcgaggtgc cgtaaagcag taaaatcgaa gggtaaacgg atgccccat ttagagcttgc 5700
acggggaaag cccgcgaacg tggcgagaaa ggaagggaag aaagcgaaaag gagcgggggc 5760
tagggcggtg ggaagtgttag gggtcacgct gggcgtaacc accacacccg ccgcgcctaa 5820
tggggcgcta cagggcgatc cggatgatc cactagt 5857

<210> 20

<211> 403

<212> DNA

<213> *Trichoderma reesei*

<220>

<223> (1-403) *T. reesei hfb2* coding sequence

<220>

<221> intron

<222> (131) .. (200)

<220>

<221> intron

<222> (287) .. (358)

<400> 20

atgcagttct tcggcgtcgc cctttcgcc accagcgccc tggctgctgt ctgccttacc 60
ggcctcttct ccaaccctct gtgctgtgcc accaacgtcc tgcacccat tggcgttgac 120
tgcaagaccc gtagttgaa ttccaatctc tggcatctt gacattggac gatacagttg 180
acttacacga tgctttacag ctaccatcgc cgtcgacact ggccgcatttcc 240
ctgtggcagc aagggtctcca agccttttgc ctgcgttgc cccgtggtaa gtatgtctcg 300
caatggcaaa gaagtaaaaaa gacattttggg cctgggatcg ctaactcttgc atatcaaggc 360
cgaccaggct ctcctgtgcc agaaggccat cgccacccat taa 403

<210> 21

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR 5' primer

<400> 21

cgaggaggct cgacgacttc gagcagcccg agctgcacgc aggctgtctg ccctaccgg 59

<210> 22

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR 3' primer

<400> 22

tcatggatc cttagaaggt gcccgtggc

<210> 23
<211> 679
<212> DNA
<213> *Schizophyllum commune*

<220>
<223> (1-679) SC3 coding sequence

<220>
<223> (1-92) 1st cDNA

<220>
<223> (146-183) 2nd cDNA

<220>
<223> (240-317) 3rd cDNA

<220>
<223> (374-469) 4th cDNA

<220>
<223> (524-586) 5th cDNA

<220>
<223> (635-679) 6th cDNA

<400> 23
atgttcgccc gtctcccggt cgtgttcctc tacgccttcg tcgcgttcgg cgccctcg 60
gctgcccctcc caggtggcca cccgggcacg acgtacgtcg acctctcacc gtccctcta 120
gtcttgcgtga tgaagccccg tatagcacgc cgccggttac gacgacggtg acggtgacca 180
cggtgagtag ctttctcgcc gtcgacgact cgaacgcatt ggctaatttt tgctctatagc 240
cgccctcgac gacgaccatc gccgtcggtg gcacgtgtac tacggggtcg ctctcttgct 300
gcaaccaggc tcaatcggtt cgtacatcaa agcggcacga ccaggcatct cagctgacgg 360
ccacatcgta caggcgagca gcagccctgt taccgcctc ctcggcctgc tcggcattgt 420
cctcagcgac ctcaacgttc tcgttggcat cagctgtct cccctcaactg tgagatctt 480
ttgttcaactg tcccaattac tgcgcaactga cagactttgc caggtcatcg gtgtcgagg 540
cagcggtgt tcggcgcaga ccgtctgtcg cgaaaacacc caattcgat gtataacttc 600
catgcgtgtc cctttctccg ctaatcatct gtagaacggg ctgatcaaca tcggttgcac 660
ccccatcaac atcctctga 679

<210> 24
<211> 63
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR 5' primer

<400> 24
actacacgga ggagctcgac gacttcgagc agcccgagct gcacgcaggg tggccacccg 60
ggc 63

<210> 25
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR 3' primer

<400> 25
tcgtacggat cctcagagga tgttatggg

30

<210> 26
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR 5' primer

<400> 26
ggaattccgc ggactgcgca tcatgaagtt ctccgcacatc gcc

43

<210> 27
<211> 80
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR 3' primer

<400> 27
tgaattccat atgttagta ccaccggggc ccatgcccgtt agaagtagaa gccccgggag 60
caccgacggc ggtctggcac 80

<210> 28
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR 5' primer

<400> 28
tgaattccgtt acccagggtt gctcaagcgt c

31

<210> 29
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR 3' primer

<400> 29
tgaattccat atgtcacagg cactgagagt agta 34

<210> 30
<211> 48
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR 5' primer

<400> 30
gaattcggta ccctcggtccc tcgcgggtccc gccgaagtga acctgggtg 48

<210> 31
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR 3' primer

<400> 31
tgaattccat atgctaacc cgtttcatct ccag 34

<210> 32
<211> 918
<212> DNA
<213> Trichoderma reesei

<220>
<221> terminator
<222> {1}..(918)
<223> T. reesei hfb1 terminator

<400> 32
gatgccccgcc cgggggtcaag gtgtgcccgt gagaaaagccc acaaagtgtt gatgaggacc 60
atttccggta ctgggaaagt tggctccacg tggttggca gggttggca agttgtgttag 120
atattccatt cgtacgcccatt tcttatttctc caatatttca gtacactttt cttcataaaat 180
caaaaagact gctattctct ttgtgacatg ccggaaaggga acaaattgctc ttggctctcg 240
ttatattgcaaa gttaggagtgg gagattcgcc tttagagaaaag tagagaagct gtgcttgacc 300
gtgggtgtgac tcgacgaggta tggactgaga gtgtttaggat taggtcgaac gttgaagtgt 360
atacaggatc gtctggcaac ccacggatcc tatgacttga tgcataatggtg aagatgaatg 420
acagtgtaaag agggaaaaggaa aatgtccgccc tttagctgtat atccacgcca atgatacagc 480
gatatacttc caaatatctgt gggAACGAGA catgacatat ttgtgggaac aacttcaaaac 540
agcgagccaa gaccccaata tgcacatcca aagccaaaca ttggcaagac gagagacagt 600
cacattgtcg tcgaaaatgtg gcatcgatcc caaatatcca gctctcattt tcgcctaaac 660
cacagattgt ttggcgccc ccaactccaa aacgttacta caaaaagacat gggcgaatgc 720
aaagacctga aagccaaaccc ttttgcgac tcaattccct cctttgtcctt cggaatgtatg 780
atccttcacc aagtaaaaaga aaaagaagat tgagataata catgaaaagc acaacggaaa 840
cgaaagaacc agggaaaagaa taaatctatc acgcacccatg tccccacact aaaagcaaca 900
gggggggtaa aatgaaat 918

<210> 33
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR 5' primer

<400> 33
gacctcgtat cccggccggg gtcaag

26

<210> 34
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR 3' primer

<400> 34
gtcgacattt cattttaccc ccctcg

26

<210> 35
<211> 1190
<212> DNA
<213> *Trichoderma reesei*

<220>
<221> promoter
<222> (1)..(1190)
<223> *T. reesei hfb2* promoter

<400> 35
ctcgagcgc tgaagcttgc atgcctgcat cctttgtgag cgactgcatac cattttgcac 60
acactgcccgt cgacgtctct ctccgcacct tggccagctg gacaaggcaac acaccaatga 120
cgctttgtat tatttagagta tatgcaagtc tcaggactat cgactcaact ctacccaccc 180
aggacgatcg cggcacgata cgccctcggtt ctcattggcc caaggcagacc aactgcccct 240
ggagcaagat tcaagcccaag ggagatggac ggcaggccac gccaggcccc caccaccaag 300
ccactccctt tggccaaatc agcttgcatac tcaagagaca tcgagctgtg ccttggaaatt 360
actaacaacc agggatggga aacgaagcct gctttggaa agacaacaat gagagagaga 420
gagagagggg gagagacaat gagtgccaca aacctggtag tgctccgcca atgcgtctga 480
aatgtcactat ccgagtcttg gggcctctgt gagaatgtcc agagtaatac gtgtttgcg 540
aatagtccctc ttcttgaggactggatacc tacgatacccttttgaggat gatgcgggtgc 600
tttcgaagta ttatctggag gatagaagac gtcttagtaa ctacacaaaaa ggccataact 660
ttggggagta gccccacgaa aggttaactcc tacggctct tagagccgtc atagatccct 720
cagccctctt gaggcgtcat agatcacatc tggtagacc gacattctat gaataatcat 780
ctcatcatgg ccacatacta ctacatactg gtctctgcct acctgacatg tagcagtggc 840
caagacacca agggcccaggc atcaagcctc cctacccatc ccttccattt tacagccgca 900
gagagattgc gatgagccct ctccctaccc acagacggct gacaatgtcc gtataccacc 960
agccaaacgtg atgaaaacaa ggacatgagg aacagcctgc gagagctgga agatgaagag 1020
ggccagaaaaaaa aaaaatataa agaagaccc tattcccgcc atccaaacaat cttttccatc 1080
ctcatcagca cactcatcta caaccatcac cacattcaact caactccctt ttctcaactc 1140
tccaaacaca aacattctt gttgaatacc aaccatcacc acctttcaag 1190

<210> 36
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR 5' primer

<400> 36
aagcttgcatttgcatcc

20

<210> 37
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR 3' primer

<400> 37
ccatggtgaa aggtgggtat ggttgg

26

<210> 38
<211> 13
<212> PRT
<213> *Trichoderma reesei*

<220>
<223> wild type *T. reesei* EGI peptide linker

<400> 38
Val Pro Arg Gly Ser Ser Ser Gly Thr Ala Pro Gly Gly
1 5 10

<210> 39
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: modified CBHII linker

<400> 39
Gly Ser Ser Ser Gly Thr Ala Pro Gly Gly
1 5 10

<210> 40
<211> 19
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Met/Thrombin linker

<400> 40

Pro Gly Arg Pro Val Leu Thr Gly Pro Gly Met Gly Thr Ser Thr Ser
1 5 10 15

Ala Gly Pro

<210> 41

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Met-containing linker

<400> 41

Pro Gly Ala Ser Thr Ser Thr Gly Met Gly Pro Gly Gly
1 5 10

<210> 42

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: linker containing the thrombin cleavage site

<400> 42

Gly Thr Leu Val Pro Arg Gly Pro Ala Gly Val Asn Leu Val
1 5 10